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Abstract
This work focuses on development of IVIVCs for variety of Q1/Q2 equivalent parenteral PLGA
microspheres with different physicochemical and release characteristics to: 1) achieve a
comprehensive understanding of impact of minor manufacturing changes on the physicochemical
properties of the microspheres and their relationship with in vitro and in vivo performance; 2)
establish Level A IVIVCs; and 3) determine whether release characteristic differences between
microspheres can affect the development and predictability of IVIVCs for a variety of
microsphere drug products.
Naltrexone and leuprolide acetate (LA) were chosen as the small molecule and peptide
microsphere model drug product, respectively. Significant differences were observed in the
physicochemical properties (such as particle size, porosity, and morphology) and release
characteristics (such as rate and duration) of the compositionally equivalent naltrexone and LA
microspheres formulations prepared with minor manufacturing changes. In addition, significant
differences in the in vitro burst release and the impact of pore diameter/structure on the release
rate were observed for the prepared peptide microsphere formulations. An accelerated in vitro
release testing method using modified USP apparatus 4 was developed as a quality control tool
for naltrexone microspheres.
The in vivo release profiles of microspheres obtained using a rabbit model were deconvoluted
using the Loo-Riegelman method, and compared with the respective in vitro release profiles. The
in vivo release profiles showed the same rank order as the in vitro release profiles but with

Janki Andhariya– University of Connecticut, [2019]
overall faster in vivo release rates. In addition, LA microspheres had significantly low in vivo
burst release, which is considered to be due to the masking effect of the absorption phase from
the intramuscular site, and this was shown to complicate the development of an IVIVC. Despite
these challenges, affirmative Level A IVIVCs were successfully developed for both microsphere
products.
Moreover, Level A IVIVCs with the ability to predict various types of burst release were
developed for the compositionally equivalent risperidone and LA microspheres. It was observed
that IVIVCs developed using formulations with less variation in burst release had better
predictability and vice-versa.
This work provides a comprehensive understanding of developing IVIVCs for complex
parenteral drug products such as microspheres.
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Chapter 1

Introduction
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1.1 Background
Polymeric microsphere products have become increasingly important as a means to
deliver drugs in a controlled manner over longer periods of time for both systemic and local
delivery.1-3 Moreover, microspheres can be formulated into injectable dosage forms that facilitate
administration and therefore patient compliance compared to bulky drug delivery
implants/devices. There are currently seventeen FDA-approved parenteral microsphere products
on the market for use as depot formulations4. Poly(lactic-co-glycolic acid) (PLGA) is the
predominant polymeric carrier for FDA approved parenteral injectable microspheres. In addition,
PLGA is used in many other FDA-approved medicines and devices mainly due to its
biodegradability, biocompatibility, and resorbability (through natural pathways)5,6. Moreover, the
rate and onset of PLGA degradation in vivo can be tailored to match specific drug release
requirements.
As several of the approved microsphere drug products are coming off patent, generic
companies are working to introduce generic equivalents. Microsphere drug products often
contain a substantial amount of potent therapeutics, which makes them “high-risk” drug products
since any unexpected change in bioavailability may result in severe side effects or toxicity. It has
been reported that the critical physicochemical properties of compositionally equivalent
polymeric microspheres (such as drug loading, particle size and porosity) are sensitive to minor
changes in the manufacturing processes, which in turn may affect drug release characteristics and
hence product performance. Accordingly, it is crucial to assure the performance and safety of
such drug products.
In vitro drug release tests must be performed to ensure their performance and safety, as
well as assist in the product development and the regulatory approval processes.7,
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However,

there is a lack of compendial in vitro release methods for microsphere dosage forms at present,
and this has hampered the development and regulatory approval of both innovator and generic
products. Hence, there is a need to develop in vitro release testing methods, that can be used to
discriminate between in and out of specification batches. In vitro release testing methods are also
necessary to support formulation, manufacturing site, scale-up and instrumentation changes.
In addition, in vivo release tests of such drug products are time consuming, labor
intensive and ethically undesirable. Hence, there is a need to develop bio-relevant in vitro release
tests such that the in vitro release profiles correlate with the in vivo release profiles, allowing the
development of an in vitro-in vivo correlation (IVIVC) or relationship (IVIVR). An IVIVC is
intended to predict accurately and precisely the expected release characteristics of a product from
the in vitro release profile. This may minimize the need to conduct in vivo release tests.
Due to the complexity of the release profiles that typically occur from microsphere
systems (bi or tri-phasic release curves), deconvolution of in vivo data and correlation with the in
vitro release profiles is challenging. This is aggravated by the lack of understanding of the
physicochemical properties of these formulations and the fact that most reported studies did not
test Q1/Q2 equivalent formulations. As a result, most studies on in vitro-in vivo release from
microspheres either report Level B IVIVCs, IVIVRs, or simple (non-mathematical) comparisons
of the in vitro and in vivo release profiles.
Our laboratory has recently demonstrated that the developed USP apparatus 4 based in
vitro release testing method is able to discriminate small molecule microsphere formulations that
are qualitatively (Q1) and quantitatively (Q2) equivalent in inactive ingredients, but have
manufacturing differences9. Most importantly, this method has shown potential in predicting in
vivo performance of the prepared Q1/Q2 equivalent microsphere formulations in a rabbit model.

3

1.2 Motivation
In order to demonstrate whether IVIVCs/IVIVRs can be achieved for a variety of
microsphere products with different physicochemical properties and release characteristics, we
proposed to investigate Q1/Q2 equivalent microsphere products containing naltrexone.
Naltrexone microspheres are commercially available (Vivitrol®). Naltrexone has different
physicochemical properties compared to risperidone (such as solubility profile) and Vivitrol® has
different release profiles compared to Risperdal Consta®.
Moreover, compared with small molecule microsphere products, protein/peptide
microsphere products are even more complex. Changes in the physicochemical characteristics of
the protein/peptide microspheres as a result of manufacturing differences, as well as the
instability of proteins/peptides during manufacturing, storage, and release in vivo may potentially
result in inconsistent in vivo performance and immunogenicity. On the other side, therapeutic
proteins and peptides are ideal for the treatment of numerous diseases as a result of their high
selectivity and their ability to provide effective and potent action at low doses. Accordingly, it is
crucial to understand the release mechanism of protein/peptide microspheres and how in vitro
studies could be used to ensure product quality and predict in vivo bioavailability. Building on
our previous research on small molecule Q1/Q2 equivalent microsphere formulations, it was then
proposed to develop IVIVCs for Q1/Q2 equivalent protein/peptide microspheres with
manufacturing differences. The therapeutic peptide, leuprolide acetate (LA) was chosen as the
model peptide since it is in commercially available microsphere products (Lupron Depot®) that
will shortly come off patent.
1.3 Specific aims
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The hypothesis of the proposed research is that, through an understanding of
microsphere physicochemical properties and their relationship to manufacturing differences for a
variety of therapeutics (i.e. small molecule and protein/peptide), an in vitro release testing
method that will result in an in vitro-in vivo correlation (or in vitro-in vivo relationship) while
also demonstrating discriminatory ability for out-of-specification formulations can be developed.
To test this hypothesis the following research objectives are proposed:
Specific Aim I: Preparation & characterization of Q1/Q2 equivalent naltrexone and leuprolide
acetate microspheres with manufacturing differences.
Specific Aim II: Development of discriminatory in vitro release testing method(s) for Q1/Q2
equivalent naltrexone and leuprolide acetate microspheres.
Specific Aim III: In vivo release testing and the development of an IVIVC/IVIVR for Q1/Q2
equivalent naltrexone and leuprolide acetate microspheres.
1.4. References
[1] K.G.M.M. Alberti, P.f. Zimmet, Definition, diagnosis and classification of diabetes mellitus
and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report
of a WHO consultation, Diabetic medicine, 15 (1998) 539-553.
[2] A.D. Association, Diagnosis and classification of diabetes mellitus, Diabetes care, 33 (2010)
S62-S69.
[3] M.J. Fowler, Microvascular and Macrovascular Complications of Diabetes, Clinical
Diabetes, 26 (2008) 77-82. [4] B. Anderson, J. Ho, J. Brackett, D. Finkelstein, L. Laffel, Parental
involvement in diabetes management tasks: relationships to blood glucose monitoring adherence
and metabolic control in young adolescents with insulin-dependent diabetes mellitus, The
Journal of pediatrics, 130 (1997) 257-265.
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[5] B. Guerci, P. Drouin, V. Grange, P. Bougneres, P. Fontaine, V. Kerlan, P. Passa, C. Thivolet,
B. Vialettes, B. Charbonnel, Self-monitoring of blood glucose significantly improves metabolic
control in patients with type 2 diabetes mellitus: the Auto-Surveillance Intervention Active
(ASIA) study, Diabetes & metabolism, 29 (2003) 587-594.
[6] W.V. Tamborlane, R.W. Beck, B.W. Bode, B. Buckingham, H.P. Chase, R. Clemons, R.
FialloScharer, L.A. Fox, L.K. Gilliam, I.B. Hirsch, Continuous glucose monitoring and intensive
treatment of type 1 diabetes, N Engl J Med, 359 (2008) 1464-1476.
[7] L.L. Samuelson, D.A. Gerber, Recent Developments in Less Invasive Technology to Monitor
Blood Glucose Levels in Patients with Diabetes, Lab Medicine, 40 (2009) 607-610.
[8] J.C. Pickup, F. Hussain, N.D. Evans, N. Sachedina, In vivo glucose monitoring: the clinical
reality and the promise, Biosensors and Bioelectronics, 20 (2005) 1897-1902.
[9] V. Lodwig, B. Kulzer, O. Schnell, L. Heinemann, Current Trends in Continuous Glucose
Monitoring, Journal of Diabetes Science and Technology, 8 (2014) 390-396.
[10] T. Henning, Commercially Available Continuous Glucose Monitoring Systems, in: In Vivo
Glucose Sensing, John Wiley & Sons, Inc., 2009, pp. 113-156.
[11] J. Morais, F. Papadimitrakopoulos, D. Burgess, Biomaterials/Tissue Interactions: Possible
Solutions to Overcome Foreign Body Response, AAPS J, 12 (2010) 188-196.
[12] J.M. Anderson, A. Rodriguez, D.T. Chang, FOREIGN BODY REACTION TO
BIOMATERIALS, Seminars in immunology, 20 (2008) 86-100.
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Chapter 2

Development of In Vitro-In Vivo Correlation of Parenteral Naltrexone Loaded Polymeric
Microspheres

7

Abstract
Establishment of in vitro-in vivo correlations (IVIVCs) for parenteral polymeric
microspheres has been very challenging, due to their complex multiphase release characteristics
(which is affected by the nature of the drug) as well as the lack of compendial in vitro release
testing methods. Previously, a Level A correlation has been established and validated for
polymeric microspheres containing risperidone (a practically water insoluble small molecule
drug). The objectives of the present study were: 1) to investigate whether a Level A IVIVC can
be established for polymeric microspheres containing another small molecule drug with different
solubility profiles compared to risperidone; and 2) to determine whether release characteristic
differences (bi-phasic vs tri-phasic) between microspheres can affect the development and
predictability of IVIVCs. Naltrexone was chosen as the model drug. Three compositionally
equivalent formulations of naltrexone microspheres with different release characteristics were
prepared using different manufacturing processes. The critical physicochemical properties (such
as drug loading, particle size, porosity, and morphology) as well as the in vitro release
characteristics of the prepared naltrexone microspheres and the reference-listed drug (Vivitrol®)
were determined. The pharmacokinetics of the naltrexone microspheres were investigated using
a rabbit model. The obtained pharmacokinetic profiles were deconvoluted using the LooRiegelman method, and compared with the in vitro release profiles of the naltrexone
microspheres obtained using USP apparatus 4. Level A IVIVCs were established and validated
for predictability. The results demonstrated that the developed USP 4 method was capable of
detecting manufacturing process related performance changes, and most importantly, predicting
the in vivo performance of naltrexone microspheres in the investigated animal model. A critical
difference between naltrexone and risperidone loaded microspheres is their respective bi-phasic
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and tri-phasic release profiles with varying burst release and lag phase. These variations in
release profiles affect the development of IVIVCs. Nevertheless, IVIVCs have been established
and validated for polymeric microspheres with different release characteristics.

9

2.1 Introduction
Owing to their advantages such as improved patient compliance and longer duration of action,
extended release drug delivery systems have attracted great attention in the past several decades,
resulting in the successful commercialization of various types of extended release drug products
[1]. Parenteral polymeric microspheres, particularly poly(lactic-co-glycolic acid) (PLGA) and
poly(lactic acid) (PLA) based microspheres have been one of the most effective non-oral
extended release drug products on the market [2]. This is due to the fact that the PLGA/PLAbased microsphere drug products are biodegradable and biocompatible with the ability to sustain
the delivery of various therapeutics (e.g. small molecules and biologics) over long periods of
time [3-6]. These microsphere drug products often contain a substantial amount of potent
therapeutics, which makes them “high-risk” drug products since any unexpected change in
bioavailability may result in severe side effects or toxicity [7]. Moreover, the critical
physicochemical properties of polymeric microspheres (such as drug loading, particle size and
porosity) are sensitive to minor changes in the manufacturing processes, which in turn may affect
drug release characteristics and hence product performance [8]. Accordingly, it is crucial to
assure the performance and safety of such drug products.
In vitro drug release testing can provide extensive insight into the release rate as well as drug
release mechanism(s) [9, 10]. Therefore, it is an important tool to not only ensure consistent
product performance and safety, but also assist in product development. When a correlation
between in vitro and in vivo drug release is established, the in vitro release method may
potentially be used as a surrogate for bioequivalence studies that would otherwise be required for
any scale-up and post-approval changes (SUPAC). The establishment of in vitro-in vivo
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correlations (IVIVCs) minimizes the need for animal studies and clinical trials, and therefore
reduces the cost and duration of generic microsphere drug product development.
In vitro-in vivo correlation (IVIVC) is a predictive mathematical model describing the
relationship between an in vitro property (e.g. rate or extent of drug release) of a dosage form
and a relevant in vivo response (e.g. plasma drug concentration or amount of drug absorbed)
[11]. The U.S. FDA has categorized four main levels of IVIVC: Levels A, B, C, and multiple
level C. A Level A IVIVC represents a point-to-point correlation between the in vitro and in vivo
input rates (e.g. the in vivo dissolution). It is considered the most informative, and is
recommended by the U.S. FDA. A Level A IVIVC is also the only level of IVIVC that can be
used to obtain a bio-waiver. In general, the U.S. FDA recommends the use of two or more
formulations with different release characteristics in order to develop a reliable IVIVC.
Unlike oral dosage forms, the establishment of an IVIVC for complex parenteral microsphere
drug products has been very challenging. This is due to not only their complex characteristics
(such as multiphase drug release profiles) but also the lack of a standard/compendial in vitro
release testing method, which can mimic and predict their in vivo performance to the maximum
extent possible [12-15]. Until now, literature reports on the establishment of IVIVCs for complex
parenteral microsphere drug products have remained sparse. Most of the reported literature is on
“proof-of-concept” research demonstrating the possibility of developing IVIVCs using one or
two microsphere formulations with different release characteristics [16-22]. Recent research has
demonstrated that a reliable Level A IVIVC can be developed for compositionally equivalent
parenteral PLGA microspheres containing water insoluble small molecule therapeutics (such as
risperidone) with manufacturing differences [8]. The drug loading as well as the burst release of
microspheres containing water soluble therapeutics tends to be highly variable with minor
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manufacturing changes. For example, the solvent exchange/evaporation rates during the
microsphere solidification process are prone to vary, which in turn may alter drug loading and
the drug release characteristics [23]. This is a very critical issue for the development of generic
microsphere products. In addition, this makes it difficult to obtain two or more compositionally
equivalent microsphere formulations with manufacturing differences for the development and
validation of IVIVCs that would be useful for generic drug product manufacturers. Due to the
solubility differences in aqueous and organic solvents, the release characteristics of such
compounds from microspheres may significantly differ from that of water insoluble compounds
(such as risperidone). For example, burst release is typically higher for water soluble compounds
as a result of drug migration to the microsphere surfaces during preparation [23, 24]. As reported
earlier, differences in the burst release affects the predictability of developed IVIVC [8]. Until
now, a Level A IVIVC has not been reported for parenteral PLGA microspheres containing
therapeutics that are soluble in water and have bi-phasic release characteristics.
The objectives of the present study were to demonstrate whether a Level A IVIVC can be
established using compositionally equivalent PLGA microspheres containing a small molecule
with different solubility profiles compared to risperidone, and to investigate whether the
differences in the release characteristics (bi-phasic vs tri-phasic) have an impact on the
predictability of IVIVCs. Naltrexone (marketed in the microsphere form as Vivitrol®) was
chosen as the model therapeutic. Three compositionally equivalent naltrexone PLGA
microspheres with manufacturing differences were prepared. The in vitro release characteristics
of the prepared naltrexone microsphere formulations and the reference listed drug (RLD) product
were determined using a previously developed USP apparatus 4 method. The pharmacokinetic
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profiles of the naltrexone microspheres were investigated using a rabbit model, and compared
with the obtained in vitro release profiles to establish an IVIVC and investigate its predictability.
2.2 Materials and Methods
2.2.1. Materials
PLGA (7525 DLG7E) was purchased from Evonik (Birmingham, AL). Anhydrous
naltrexone base was purchased from Mallinckrodt Pharmaceuticals (St. Louis, MO). Poly (vinyl
alcohol) (PVA, MW 30-70 kDa), trifluoroacetic acid (TFA), benzyl alcohol (BA) and the
reference standard (i.e. naltrexone-D3) were purchased from Sigma-Aldrich (St. Louis, MO).
Methylene chloride (DCM), ethyl acetate (EA), and dimethyl sulfoxide (DMSO, ACS grade)
were purchased from Fisher Scientific (Pittsburgh, PA). LC-MS grade 0.1% v/v formic acid
water and methanol were purchased from VWR (Radnor, PA). Milli-Q® water (Barnstead,
Dubuque, IA) was used for all studies. All other chemicals were obtained commercially as
analytical-grade reagents.
2.2.2. Preparation of naltrexone microspheres
PLGA (7525 DLG7E, Mw >100KD) with similar molecular weight as that used in the
commercial product Vivitrol® was used to formulate compositionally equivalent naltrexone
microspheres using different manufacturing processes. Briefly, 250 mg of PLGA was dissolved
in organic solvent (i.e. ethyl acetate (16.7%, w/v) or methylene chloride (25%, w/v)). Naltrexone
is poorly soluble in both methylene chloride and ethyl acetate and accordingly, a co-solvent
(benzyl alcohol) was used to facilitate dissolution of naltrexone. The polymer solution was added
to the naltrexone solution in benzyl alcohol (30%, w/v). The organic phase containing both the
polymer and drug was then dispersed into a 1% (w/v) PVA solution (0.22 µm membrane
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filtered), and an oil-in-water (o/w) emulsion was prepared by employing size reduction
techniques such as homogenization (3,200 rpm for 60 sec) (IKA® Works, Inc.) and magnetic
stirring (600 rpm for 15 min). The PVA solution was saturated with organic solvents (i.e. 1.8 and
8.5 % (v/v) in the case of methylene chloride and ethyl acetate, respectively) in order to prevent
abrupt precipitation of the polymer during emulsification. The resultant o/w emulsion was added
to water (125 mL) and stirred at 220 rpm for 15 h to allow microsphere solidification. The
organic solvents were then removed under vacuum at room temperature. The resultant
microspheres retained on a 25 µm sieve were collected and washed using an aqueous ethanol
solution (25% (v/v), <5°C). Lyophilization was used to dry the microspheres.
2.2.3. Characterization of naltrexone microspheres
2.2.3.1. High performance liquid chromatography (HPLC) analysis
The quantification of naltrexone was conducted using a PerkinElmer HPLC system (series
200) with a UV absorbance detector (PerkinElmer, Shelton, CT) set at 210 nm. The mobile phase
was 10 mM phosphate buffer (pH 6.6)/methanol (35/65, v/v), and the flow rate was 1 mL/min. A
Zorbax® C18 column (150 x 4.6 mm, 5 µm; Agilent technologies) was used as the stationary
phase. The sample injection volume was 10 µL for drug loading and 50 µL for in vitro release
testing sample analysis. The chromatographs were analyzed using a PeakSimple™
Chromatography System (SRI instruments, Torrance, CA).
2.2.3.2. Drug loading
The naltrexone microspheres (~4 mg) were weighed and transferred into 10 mL volumetric
flasks. DMSO (2.5 mL) was added into the volumetric flasks and the samples were sonicated
until all particles were dissolved. Methanol was used to dilute the sample. The solutions were
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filtered (Millex® HV, 0.22 µm PVDF syringe filter) and the naltrexone concentrations were
determined via the validated HPLC assay as described above. Drug loading was calculated as:

Drug Loading (%) =

weight of drug entrapped
× 100
weight of microspheres analyzed

2.2.3.3. Particle size and size distribution
Particle size and particle size distribution of the naltrexone microspheres were measured
using an AccuSizer autodiluter particle sizing system (Nicomp, Santa Barbara, CA). Briefly, the
microspheres were dispersed in a filtered 0.1% (w/v) PVA solution in water to ensure good
dispersion, and then particle size analysis was conducted.
2.2.3.4. Differential scanning calorimeter (DSC) analysis
The glass transition temperatures (Tg) of the naltrexone microspheres were analyzed using a
modulated temperature differential scanning calorimeter (MTDSC) (TA Instruments Q2000).
Briefly, experiments were performed in hermetically sealed pans using a 2°C/min heating rate
and a modulation amplitude of ± 0.82°C with an 80 s modulation period. The weight of each
sample was ~ 5-6 mg. The Tg was determined as the glass transition midpoint in the reversing
signal.
2.2.3.5. Morphology
The morphology of the commercial product Vivitrol® and the prepared naltrexone
microspheres was analyzed using scanning electron microscopy (SEM). Briefly, dry
microspheres were mounted on carbon taped aluminum stubs and sputter coated with gold under
an argon evaporator and high vacuum. The samples were then observed using SEM (NanoSEM
450, Nova).
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2.2.3.6. Porosity
The porosity of the commercial product and the prepared naltrexone microspheres was
determined using a Mercury Porosimeter (AutoPore IV 9500, Micromeritics). Briefly,
approximately 200 mg of naltrexone microspheres were introduced into the porosimeter and
tested at a mercury filling pressure of 0.53 psi. Total intrusion volume, total pore area as well as
porosity (%) were recorded.

Porosity (%) = (1 −

Bulk density
) × 100
Apparent (skeletal)density

2.2.4. In vitro release studies
In vitro release testing of the prepared naltrexone microspheres and the commercial product
was conducted using a previously developed modified USP apparatus 4 method at 37°C [25].
Briefly, 10 mg of microspheres were mixed with glass beads (1 mm) and placed in the USP
apparatus 4 dissolution cells. 50 mL of phosphate buffered saline (PBS) (10 mM, pH 7.4)
containing 0.02% (v/v) Tween 20 and 0.02% (w/v) sodium azide was circulated through the flow
through cells at a flow rate of 8 mL/min at 37 °C. At pre-determined time intervals, one mL of
samples were withdrawn and replenished with fresh media. The obtained samples were analyzed
via HPLC. The release medium was replaced with fresh release medium every five days to avoid
drug degradation. Media replacement during release testing was taken into account in the
calculation of the fraction release. All drug release tests were conducted in triplicate and the
results are reported as the mean % cumulative release ± SD.
2.2.5. In vivo release studies
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The in vivo release characteristics of the prepared naltrexone microspheres and the
commercial product were investigated using a rabbit model. Briefly, male rabbits (New Zealand
White) weighing approximately 3 to 4 kg were randomly assigned to each treatment group (n =
6). The naltrexone microspheres were suspended in the diluent used for dispersion of the
commercial product Vivitrol®, and injected into the rabbit hind leg thigh muscles at a dose of
11.69 mg/kg. Blood samples were collected from the marginal ear veins at predefined time
intervals. In addition, a pharmacokinetic study of the naltrexone solution in saline (dose: 0.11
mg/kg, i.v.) was conducted (n = 6). The collected blood samples were centrifuged at 14,500 rpm
for 5 min to separate out the plasma. The plasma was collected and stored at -80°C until analysis.
The animal study protocol was reviewed and approved by the University of Connecticut's
Institutional Animal Care and Use Committee (IACUC) prior to the beginning of the
experiments.
2.2.6. Plasma sample analysis
Naltrexone was extracted from plasma samples using tert-butyl methyl ether by a liquidliquid extraction method. Naltrexone D-3 was used as the internal standard. Briefly, the internal
standard solution (100 ng/mL, 20 µL) was added to 100 µL plasma samples. Samples were
vortex-mixed for 5 min followed by addition of tert-butyl methyl ether (1 mL). Then the samples
were vortex-mixed again for 15 min followed by centrifugation (4°C) at 14,500 rpm for 5 min.
The supernatants were collected in polypropylene centrifugation tubes and the solvent was
evaporated under nitrogen flow. The dry residues were then reconstituted with methanol (150
μL) and injected into a LC-MS/MS system for sample analysis.
The LC-MS/MS system consisted of an Agilent HP-1100 LC system and a TSQ Quantum
Ultra Mass Spectrometer (Waters) with an electrospray ionization (ESI) ion source.
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Chromatographic separations were carried out on a Kinetex HILIC column (50 x 2.1 mm, 2.6
μm, 100 Å) through an isocratic mobile phase (0.1 % (v/v) formic acid in water/methanol (20/80,
v/v)) at 30°C. The following MS detection parameters were used: 4000 V electrospray voltage,
360°C capillary temperature, collision pressure 3.0, and 30 V collision energy. Detection of
daughter ions was conducted in the positive-ion selected reaction monitoring mode with the
following transitions in a single reaction monitoring (SRM) mode: m/z 342 (naltrexone) to m/z
324.2 (dehydronaltrexone, daughter ion), and m/z 345.2 (naltrexone-D3) to m/z 327.2
(dehydronaltrexone-D3, daughter ion). The injection volume was 15 μL. The data acquisition
was ascertained by Xcalibur software. Calibration curves were established on each day when
analysis was conducted, and showed good linearity with correlation coefficients > 0.99. The
lowest limit of quantification (LLOQ) for naltrexone was 0.5 ng/mL and the mean recovery of
plasma samples from low to high concentrations of naltrexone was more than 90%. The interand intra-day variations of the three different concentrations of naltrexone (0.5, 10, and
20 ng/mL) were less than 15%.
2.2.7. Pharmacokinetic analysis and the development of an IVIVC
The development of IVIVC for the prepared naltrexone PLGA microspheres was performed
following the same principles as detailed in the U.S. FDA guidance on development of IVIVC
for extended release oral dosage forms [11]. Briefly, the in vivo plasma profiles of naltrexone
PLGA microspheres were deconvoluted using the Loo-Riegelman method [14, 26]. Standard
errors are not shown in the deconvoluted in vivo absorption profiles because the average plasma
concentration values were used. The fraction absorbed in vivo was calculated as below:
𝐴𝑏
𝐴𝑏∞

=

𝐶𝑝 +𝐶𝑡 +𝐾10 (𝐴𝑈𝐶)𝑡0
𝐾10 (𝐴𝑈𝐶)∞
0
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Cp, Ct, K10 and AUC are the drug concentration in the central compartment (plasma),
apparent tissue compartment concentration, elimination rate constant and area under the plasma
vs time curve, respectively. The distributive and elimination micro rate constants (k12, k21 and
k10) that are necessary for calculating Ct, and the total fraction absorbed at time t, were calculated
using WinNonlin® 6.4 (Pharsight, Certara corporation St.Louis, USA) based on the plasma
concentrations of naltrexone after intravenous administration of the naltrexone solution.
The development and validation of the IVIVC for the naltrexone microspheres were
performed using WinNonlin® 6.4 (Pharsight, Certara corporation St. USA).
2.2.8. Statistical data analysis
Statistical analysis was performed to evaluate significant differences between different
microsphere formulations using a paired student t-test. The level of significance was accepted
at p < 0.05.
2.3. Results and Discussion
2.3.1. Physicochemical properties of naltrexone microspheres
It has been reported that the critical physicochemical properties (e.g. particle size, and
porosity) of parenteral PLGA microspheres containing a water insoluble model compound
(risperidone) are sensitive to minor changes in manufacturing processes (such as solvent systems
and particle size reduction technique) [8]. In order to understand the effect of manufacturing
processes on the physicochemical properties of parenteral PLGA naltrexone microspheres that
were prepared using different manufacturing processes, three compositionally equivalent
naltrexone microspheres were obtained: 1) Formulation 1_stirring (methylene chloride and
benzyl alcohol solvent system); 2) Formulation 2_stirring (ethyl acetate and benzyl alcohol
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solvent system); and 3) Formulation 3_homogenization (ethyl acetate and benzyl alcohol solvent
system).
The physicochemical properties of the prepared naltrexone microspheres with manufacturing
differences and the RLD product are presented in Table 1. As shown in Table 1, all naltrexone
microsphere formulations had similar drug loading (ca. 29%, w/w), and the RLD product had a
slightly higher drug loading (33.5%). It was observed that maintaining high drug loading of the
naltrexone microspheres was very challenging, since water soluble compounds can leak into the
larger outer aqueous phase during the microsphere solidification process, resulting in low drug
loading. Lower temperature (4°C) was used throughout the preparation process to minimize drug
diffusion from the inner organic phase droplets into the aqueous phase. It has previously been
reported that the polymer precipitation rate facilitates entrapment of most of the drug inside the
core and hence, is critical to achieve high drug loading for hydrophilic drugs [23]. In the present
study, solvent removal and consequent, polymer precipitation were controlled by continuously
applying a vacuum at a constant pressure to achieve fast solvent evaporation and therefore fast
microsphere solidification, to minimize drug loss into the aqueous phase during preparation.
Particle size and particle size distribution of all three prepared naltrexone microsphere
formulations and Vivitrol® are shown in Figure 1. Despite the fact that all the formulations were
prepared using different manufacturing processes, the prepared naltrexone microspheres showed
similar D50 values in terms of population distribution (ca. 50 μm), which were similar to that of
Vivitrol®. Whereas, in the case of volume distribution, Formulation 3 showed a smaller D50
value (ca. 68 μm) compared to Vivtrol® and the other two prepared formulations (ca. >100 μm)
(p < 0.05). In addition, the span value of Formulation 3 was the lowest compared to that of
Vivitrol® and Formulations 1 and 2, which indicates narrow size distribution. The microspheres
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prepared using the stirring technique (i.e. Formulations 1 and 2) showed a large variation in the
particle size distribution, while the microspheres prepared using the homogenization method (i.e.
Formulation 3) showed comparatively smaller but uniform particle size. This can be explained
by the fact that the homogenization process provided a stronger emulsification force, thus
leading to a smaller particle size with a narrower size distribution compared to the stirring
process.
Table 1. Physicochemical properties of naltrexone microspheres investigated.
Sample

Solvent

Preparation

Drug

Porosity

Method

Loading

(%, w/w)

(%, w/w)
Formulation 1

DCM&BA

Magnetic Stirring

28.74±1.64

49.83

Formulation 2

EA&BA

Magnetic Stirring

29.7±1.11

58.32

Formulation 3

EA&BA

Homogenization

29.57±1.75

65.08

Vivitrol®

-

-

33.50±1.43

50.21

DCM: methylene chloride, EA: ethyl acetate, BA: benzyl alcohol
140

2.50

D50 Value

A
Particle Size (µm)

Span Value

B

120

2.00

100

1.50

80

*

60

1.00

40

0.50
20

0.00

0
Vivitrol®

Formulation_1

Population distribution

Formulation_2

Formulation_3

Vivitrol®

Formulation_1

Population distribution

Volume distribution

Formulation_2

Formulation_3

Volume distribution

Figure 1. Particle size and particle size distribution of Vivitrol® and the naltrexone microspheres
prepared using different manufacturing processes. (A) D50 value; and (B) span value. All values
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are expressed as mean ± SD (n = 3 batches) (* represents statistically different particle size
compared to Vivitrol®).
Differences in the manufacturing processes (such as different solvents, and rates of solvent
diffusion and evaporation) have been reported to affect the inner structure and/or the porosity of
PLGA microspheres [27, 28]. As shown in Figure 2, all the prepared naltrexone microspheres
were polydispersed, and of a spherical shape with the presence of a few large pits on their
surfaces. The presence of large pits on the microsphere surfaces may be due to shrinkage during
the solvent evaporation process under vacuum. Furthermore, the naltrexone microspheres
prepared using methylene chloride as the solvent (i.e. Formulation 1) had a lower percentage
porosity (49.83%) compared to those microspheres prepared using ethyl acetate & benzyl
alcohol as the solvent system (58.32% and 65.02% for Formulations 2 and 3, respectively)
(Table 1). Since ethyl acetate is relatively more miscible with water compared to methylene
chloride, water inclusion during microsphere solidification led to the formation of a porous core
structure and hence higher porosity, which is consistent with our recent research on risperidone
PLGA microspheres [29]. No significant differences were observed in the Tg of the naltrexone
microspheres.

A

B

200 μm

C

200 μm

D

200 μm

200 μm

Figure 2. SEM micrographs of the commercial product, Vivitrol® (A); Formulation 1 (B);
Formulation 2 (C); and Formulation 3 (D). Symbol: The red arrows point to the pits of the
microsphere surfaces.
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Overall, it was observed that the critical quality attributes of the naltrexone microspheres
(such as drug loading, particle size and porosity) are very sensitive to manufacturing differences
such as the solvent system, the solvent removal rate, temperature and the particle size reduction
technique. It was anticipated that the differences in these critical quality attributes of naltrexone
microspheres may affect their in vitro and in vivo performance.
2.3.2. In vitro release characteristics of naltrexone microspheres
One of challenges in developing an IVIVC for complex parenteral drug products (such as
microspheres) is the lack of compendial in vitro release testing methods. Various methods have
been used to investigate in vitro release profiles of parenteral polymeric microspheres, including
sample-and-separate, dialysis and USP apparatus 4 methods [10, 30-32]. The 2004 AAPSEUFEPS workshop recommended a dissolution method using USP apparatus 4 for microspheres
[12]. An effort has recently been made to develop a suitable in vitro release testing method for
naltrexone microspheres [25]. However, due to instability issues associated with naltrexone,
frequent media replacement was determined to be necessary during long-term release testing to
avoid oxidative degradation. Based on recent research, a USP apparatus 4 method with excellent
reproducibility was used to investigate the in vitro release characteristics of the naltrexone
microspheres [25].
As shown in Figure 3, the developed “real-time” USP apparatus 4 method was able to
discriminate between the in vitro release profiles of all the prepared naltrexone microsphere
formulations with manufacturing differences and also Vivitrol®. Unlike the previously reported
risperidone microspheres [8], the naltrexone microspheres investigated showed bi-phasic release
profiles, indicating naltrexone release from these microspheres may be governed by a
combination of drug diffusion and polymer degradation. Drugs that are soluble in water can
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more easily diffuse into the release media compared to water insoluble compounds such as
risperidone. Hence, there may be continuous release of drug from microsphere pores even in the
absence of polymer degradation. Consequently, such drugs encapsulated in PLGA microspheres
may have bi-phasic release profiles with no or very short lag phase.
Formulations 1 and 2 reached more than 90% release at around day 40 and day 30,
respectively, and had initial lag phases of approximately five days compared to Vivitrol® and
Formulation 3, which did not have a lag phase (Figure 3). The naltrexone microspheres prepared
using the homogenization method (Formulation 3) which had a small and uniform particle size
distribution as well as a highly porous structure, exhibited a much faster release rate and
plateaued at around day 20. This can be compared to Formulations 1 and 2, which had larger
particle size and longer release duration. Small microspheres have a shorter diffusion distance
and the highly porous structure of Formulation 3 also facilitates diffusion. In addition, the
increased water penetration leads to faster polymer degradation, which also facilitates drug
release. Among the three prepared naltrexone microsphere formulations, Formulation 2 had an
intermediate release rate due to its larger particle size compared to Formulation 3, and its higher
porosity compared to Formulation 1. Formulation 1 showed the slowest release profile. This is
considered to be a result of the low porosity and large particle size of Formulation 1 (Table 1).
Interestingly, all the prepared naltrexone microsphere formulations showed low burst release.
This was achieved by the use of low temperature (4°C) and high vacuum throughout the
microsphere preparation process, which increases the polymer precipitation rate causing the drug
to be entrapped within the microsphere matrix, resulting in a low burst release percentage.
Furthermore, the in vitro release profile of the RLD product was initially similar to Formulation
3 with no lag phase, however the release rate and duration were closest to Formulation 1. The

24

RLD product may be prepared via a different manufacturing process and/or with a different
PLGA polymer. These results reaffirm, using another small molecule model compound, that the
in vitro release characteristics of PLGA microspheres are very sensitive to changes in the
manufacturing processes.

Cumulative Naltrexone Released (%)

100
90
80
70
60

Formulation 1

50

Formulation 2

40

Formulation 3

30

Vivitrol®

20
10
0
0

5

10

15

20

25

30

35

40

Time (day)

Figure 3. In vitro release profiles of compositionally equivalent naltrexone microsphere
formulations (with manufacturing differences) and Vivitrol®. The developed USP apparatus 4
method was used at 37°C in 10 mM PBS (pH 7.4) containing 0.02% (w/v) Tween 20 and 0.02%
(w/v) sodium azide (n = 3). The release media was replaced every five days.
2.3.3. In vivo release characteristics of naltrexone microspheres
The pharmacokinetic profiles of the naltrexone solution following single intravenous
administration (i.v.), and of the naltrexone microspheres following intramuscular administration
(i.m.) in rabbits are shown in Figures 4A and 4B, respectively. The in vivo profiles of all
naltrexone microspheres (Figure 4B) were determined to have good correlation with their
respective in vitro release profiles (Figure 3). Formulation 1 showed a slower absorption peak
(Tmax, Day 5) with the longest absorption/release duration (30 days) compared to the other
naltrexone microspheres investigated. Formulation 2 had an intermediate absorption peak (Tmax,
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Day 4) as well as an overall intermediate absorption/release duration (22 days), while
Formulation 3 had the earliest absorption peak (Tmax, Day 2) with the shortest absorption/release
duration (15 days). These results are in line with the in vitro release profiles and with the
differences in the porosity and mean particle size among the three formulations, as discussed
above.
In Vivo Release Profiles in rabbits (n=6)
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Formulation 1

16

Formulation 2
12
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Vivitrol®
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0
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20

24
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32

Time (day)

Figure 4. Mean plasma concentration-time profiles of naltrexone in rabbits following: (A)
intravenous administration of the naltrexone solution at a single dose of 0.11 mg/kg; and (B)
intramuscular administration of naltrexone PLGA microspheres at a single dose of 11.69 mg/kg
(mean ± SD, n = 6).
Key pharmacokinetic parameters of the naltrexone solution following i.v. administration
were analyzed using WinNonlin® 6.4 (Pharsight, Certara corporation, St. Louis, USA) and are
shown in Table 2. These pharmacokinetic parameters were used to deconvolute the
pharmacokinetic profiles ((i.m.) of the naltrexone microspheres investigated using the LooRiegelman method [26]. As shown in Figure 5, the deconvoluted in vivo profiles of the Vivitrol®
and the prepared naltrexone microspheres followed the same rank order as their in vitro release
profiles: Formulation 3 > Formulation 2, Vivitrol® > Formulation 1 (Figure 3). It is also
significant to note, that both Vivitrol® and Formulation 3 do not show evidence of a lag phase in
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vivo and this is consistent with their in vitro release profiles, whereas Formulations 1 and 2,
which showed a lag phase in their in vitro release profiles also showed evidence of a change in
the release rate in vivo around day four.
The deconvoluted in vivo release profiles appeared to be faster compared to their respective
in vitro release profiles (Figure 3). As reported previously, this might be due to enhanced
polymer degradation as a result of local acidic pH [18, 20] and the presence of other biological
components (such as enzymes [33]) accelerating polymer degradation and thereby drug release
in vivo. Moreover, the in vivo drug release profile of Vivitrol® in rabbits appeared to have a
slightly shorter duration with a faster release rate compared to the clinical data reported in
literature [34]. This is consistent with our recent research on risperidone microspheres, where the
rabbit pharmacokinetic data were significantly faster than the clinical data [8]. It is suspected that
the differences in the local environment (such as interstitial fluid volume, blood flow and the
presence of other biological components) between the rabbit hind leg thigh muscle and human
gluteal muscle as well as differences in drug metabolism may be responsible for the interspecies
differences in the pharmacokinetics of both naltrexone and risperidone and their respective
microsphere formulations [35].
Table 2. Pharmacokinetic parameters of the naltrexone solution following intravenous
administration (n=6).
A

B

α (h-1)

β (h-1)

K10 (h-1)

K12 (h-1)

K21 (h-1)

38.45±7.35 1.98±0.820 1.12±0.169 0.12±0.047 0.80±0.119 0.28±0.058 0.17±0.067
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Figure 5. In vivo fraction absorbed/released profiles (i.m.) of naltrexone microspheres prepared
with manufacturing differences and Vivitrol® (deconvoluted using the Loo-Riegelman method
from the data presented in Figure 4).
It was demonstrated that despite all the prepared naltrexone microspheres being
compositionally equivalent, they had different in vitro and in vivo drug release characteristics
due to the differences in their physicochemical characteristics resulted from different
manufacturing processes.
2.3.4. IVIVC
The “Guidance for industry, extended release oral dosage forms” recommends the use of a
minimum of two, preferably three or more formulations with different release rates to develop an
IVIVC if the in vitro release of the formulations is dependent on the release testing
conditions [11]. It has been previously demonstrated that naltrexone release from the prepared
microsphere formulations was dependent on the release testing conditions (such as pH, medium
additives and temperature) [25]. Accordingly, all three prepared naltrexone microsphere
formulations with different in vitro and in vivo drug release characteristics (Figures 3 and 4B)
were used to develop and validate an IVIVC. The fraction absorbed/released in vivo of any
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combination of two formulations out of the three prepared naltrexone microsphere formulations
was plotted against the time-shifted fraction released in vitro at the respective time points to
determine the correlation if any. The time-shifting factor (5.2) was kept the same for all
naltrexone microspheres investigated. As shown in Figure 6 (A, C and E), an affirmative IVIVC
(i.e. a Level A, point-to-point correlation, as per U.S. FDA guidance) between the fractions
released in vitro and fractions released/absorbed in vivo was observed for all combinations
(correlation coefficients greater than 0.94). All the developed IVIVCs were comparable as
manifested by similar slopes and intercepts.
The IVIVC equation obtained using two internal formulations was used to predict the in vivo
performance of the third external formulation from its “real-time” in vitro release profile. The
predicted in vivo profile of the third external formulation was compared with its deconvoluted in
vivo profiles obtained in rabbits. As shown in Figure 6 (B, D and F), the predicted in vivo
profiles of Formulations 1 and 2 were similar to the observed in vivo profiles with no significant
difference. However, that of Formulation 3 did show differences, particularly within the first 8
days. This may be due to the dissimilarity in the drug release profile of Formulation 3 compared
to Formulations 1 and 2, in that Formulation 3 does not exhibit a lag phase.
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Figure 6. Level A IVIVC developed for naltrexone microspheres using the Loo-Reigelman
method (time shifting factor: 5.2). (A) IVIVC_1 (developed using Formulations 1 and 2). (B)
Experimental and predicted in vivo release profiles of Formulation 3. (C) IVIVC_2 (developed
using Formulations 2 and 3). (D) Experimental and predicted in vivo release profiles of
Formulation 1. (E) IVIVC_3 (developed using Formulations 3 and 1). (F) Experimental and
predicted in vivo release profiles of Formulation 2.
The in vivo release profile of the commercial product Vivitrol® was also predicted from its
“real-time” in vitro release profile using all three developed IVIVCs, and compared with its
observed in vivo profile (deconvoluted) obtained in rabbits. As shown in Figure 7, all three
predicted in vivo release profiles were similar to the observed in vivo profiles, irrespective of
which developed IVIVC was used. However, during the initial release period (of approximately
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four to five days), the predicted release profile of Vivitrol® was slightly higher than that
observed. It would appear that microsphere formulations with and without a lag phase are not
ideal predictors of one another. A similar observation has been reported for compositionally
equivalent risperidone microsphere formulations with manufacturing differences, where
formulations with high burst release were not ideal predictors for formulations with low burst
release. However, for the compositionally equivalent risperidone microspheres, the developed
IVIVCs showed acceptable predictability in terms of % prediction error of AUC0-last and Cmax as
per U. S. FDA guidance irrespective of differences in burst release.
Vivitrol®
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In vivo release profile (n=6)
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Figure 7. Experimental and predicted (time shifting factor: 5.2) in vivo release profiles of
Vivitrol® using the developed IVIVCs. IVIVC_1 developed using Formulations 1 and 2.
IVIVC_2 developed using Formulations 2 and 3. IVIVC_3 developed using Formulations 3 and
1.
The internal validation of the developed IVIVC model was accomplished by convolving the
in vitro/in vivo release data of Formulations 1 and 3, since Formulations 1 and 3 had the slowest
and fastest release rates. Table 3 represents the %prediction error (PE) values for the Cmax and
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AUC of these two formulations. The PE% values of the Cmax and AUC of Formulation 1 were 1.68 and -12.16, respectively. The PE% values of the Cmax and AUC of Formulation 3 were 22.24 and -1.92, respectively. The average absolute %PE value of Cmax and AUC were 11.96
and 7.04, respectively. As per the U.S. FDA guidance [11], the predictability can be acceptable
when the average absolute %PE values are of 10% or less and the %PE value for each
formulation should not exceed 15%. In the present study, the average absolute internal %PE for
the AUC (7.04%) was within the recommended range of 10% or less. However, the average
absolute internal %PE for Cmax (11.96%) was slightly more than 10%, suggesting the internal
predictability of the developed IVIVC for Cmax was inconclusive. The FDA guidance states that
if the criteria for internal validation are not met, the external predictability should be evaluated as
the final determination of the IVIVC model.

Accordingly, the evaluation of external

predictability of the IVIVC was performed. It can be seen in Table 3 that the external %PE for
Cmax and AUC0-last were 3.38% and 10.13%, respectively, which is in accordance with the
recommended external predictability evaluation (%PE of 10% or less). These results indicate that
the developed IVIVC has good external predictability, thus could be used as a surrogate for
bioequivlance in rabbits. Furthermore, the predictability of the developed IVIVC for Vivtrol®
was also investigated. Both %PEs for Cmax (-9.27%) and AUC0-last (9.53%) were below 10%.
These results confirmed that the developed IVIVC for naltrexone microspheres can be used to
predict not only the prepared compositionally equivalent formulations with manufacturing
differences but also a microsphere formulation with relatively similar composition and drug
loading.
Table 3. Validation and % prediction error (PE) of the developed IVIVC for naltrexone
microspheres.
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Cmax (μg/L)

AUC0-last (μg/L* day)

Internal validation

Obs.

Pred.

%PE

Obs.

Pred.

%PE

Formulation1

7.98

7.84

-1.68

80.82

70.99

-12.16

Formulation 3

18.78

14.61

-22.24

72.17

70.79

-1.92

Average Internal

11.96

7.04

External Validation
Formulation 2

7.49

7.74

3.38

62.78

69.14

10.13

7.54

6.84

-9.27

74.60

81.70

9.53

Prediction
Vivitrol®

2.4. Conclusions
The present manuscript describes for the first time that a Level A IVIVC based on a
compendial dissolution apparatus (USP apparatus 4) can be developed for compositionally
equivalent PLGA microspheres containing a therapeutic that is water soluble (i.e. naltrexone),
and for PLGA microspheres with bi-phasic release characteristics. The critical quality attributes
of the naltrexone microspheres (such as drug loading, particle size, and porosity) were very
sensitive to manufacturing differences such as solvent system, solvent removal rate, and
temperature as well as the particle size reduction technique. It was shown that solvent removal,
drug diffusion and polymer precipitation during microsphere solidification must be closely
controlled in order to maintain consistently high drug loading for microspheres containing
hydrophilic therapeutics. The developed USP apparatus 4 method was able to detect in vitro
performance changes resulting from manufacturing processes differences and most importantly,
predict in vivo performance of the naltrexone microspheres. Due to the instability issues
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associated with naltrexone, frequent medium replacement was implemented during long-term
release testing to prevent oxidative degradation of naltrexone. Together with our previous
research on developing a Level A IVIVC for polymeric microspheres containing a water
insoluble therapeutic (e.g. risperidone) with tri-phasic release characteristics, it can be concluded
that Level A IVIVCs can be developed for parenteral microsphere drug products using USP
apparatus 4 in a rabbit model. However, considering the interspecies differences between
animals and humans, further investigation is necessary to determine whether an IVIVC can be
developed using clinical data. In addition, it would appear that care should be taken in
developing and applying IVIVCs to formulations with significant differences in burst release and
lag phases.
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[17]Blanco-Prıé to M. a. J., Campanero M. A., Besseghir K., Heimgatner F. and Gander B.,
Importance of single or blended polymer types for controlled in vitro release and plasma levels
of a somatostatin analogue entrapped in PLA/PLGA microspheres, Journal of controlled release.
96 (2004) 437-448.
[18]Chu D.-F., Fu X.-Q., Liu W.-H., Liu K. and Li Y.-X., Pharmacokinetics and in vitro and in
vivo correlation of huperzine A loaded poly (lactic-co-glycolic acid) microspheres in dogs,
International journal of pharmaceutics. 325 (2006) 116-123.
[19]Vlugt-Wensink K., De Vrueh R., Gresnigt M., Hoogerbrugge C., van Buul-Offers S., De
Leede L., Sterkman L., Crommelin D., Hennink W. and Verrijk R., Preclinical and clinical in
vitro in vivo correlation of an hGH dextran microsphere formulation, Pharmaceutical research.
24 (2007) 2239-2248.
[20]Zolnik B. S. and Burgess D. J., Evaluation of in vivo–in vitro release of dexamethasone from
PLGA microspheres, Journal of controlled release. 127 (2008) 137-145.
[21]Rawat A., Bhardwaj U. and Burgess D. J., Comparison of in vitro–in vivo release of
Risperdal® Consta® microspheres, International journal of pharmaceutics. 434 (2012) 115-121.
[22]D'Souza S., Faraj J. A., Giovagnoli S. and DeLuca P. P., IVIVC from long acting olanzapine
microspheres, International journal of biomaterials. 2014 (2014).
[23]Perez M. H., Zinutti C., Lamprecht A., Ubrich N., Astier A., Hoffman M., Bodmeier R. and
Maincent P., The preparation and evaluation of poly (ϵ-caprolactone) microparticles containing
both a lipophilic and a hydrophilic drug, Journal of Controlled Release. 65 (2000) 429-438.

36

[24]Jameela S., Suma N. and Jayakrishnan A., Protein release from poly (ε-caprolactone)
microspheres prepared by melt encapsulation and solvent evaporation techniques: a comparative
study, Journal of Biomaterials Science, Polymer Edition. 8 (1997) 457-466.
[25]Andhariya J. V., Shen J. and Burgess D. J., Accelerated in vitro release teting method for
naltrexone loaded PLGA-microsphere International Journal of Pharmaceutics. 520 (2017) 79-85.
[26]Wagner J. G., Application of the Loo-Riegelman absorption method, Journal of
pharmacokinetics and biopharmaceutics. 3 (1975) 51-67.
[27]Li M., Rouaud O. and Poncelet D., Microencapsulation by solvent evaporation: State of the
art for process engineering approaches, International Journal of pharmaceutics. 363 (2008) 2639.
[28]Xiao C.-D., Shen X.-C. and Tao L., Modified emulsion solvent evaporation method for
fabricating core–shell microspheres, International journal of pharmaceutics. 452 (2013) 227-232.
[29]Sah H., Microencapsulation techniques using ethyl acetate as a dispersed solvent: effects of
its extraction rate on the characteristics of PLGA microspheres, Journal of Controlled Release.
47 (1997) 233-245.
[30]Zolnik B., Raton J. and Burgess D., Application of USP apparatus 4 and in situ fiber optic
analysis to microsphere release testing, Dissolution Technol. 12 (2005) 11-14.
[31]Larsen C., Larsen S. W., Jensen H., Yaghmur A. and Østergaard J., Role of in vitro release
models in formulation development and quality control of parenteral depots, Expert opinion on
drug delivery. 6 (2009) 1283-1295.
[32]Rawat A., Stippler E., Shah V. P. and Burgess D. J., Validation of USP apparatus 4 method
for microsphere in vitro release testing using Risperdal® Consta®, International journal of
pharmaceutics. 420 (2011) 198-205.

37

[33]Lu Y., Sturek M. and Park K., Microparticles produced by the hydrogel template method for
sustained drug delivery, International journal of pharmaceutics. 461 (2014) 258-269.
[34]FDA Psychopharmacologic drugs advisory, Vivitrol® (naltrexone for extended-release
injectable suspension), committee meeting, NDA 21-897, 16 September 2010 (advisory
committee briefing materials: available for public release), (2010).
[35]Schliecker G., Schmidt C., Fuchs S., Ehinger A., Sandow J. and Kissel T., In vitro and in
vivo correlation of buserelin release from biodegradable implants using statistical moment
analysis, Journal of controlled release. 94 (2004) 25-37.

38

Chapter 3

Accelerated In Vitro Release Testing Method for Naltrexone Loaded PLGA Microspheres
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Abstract
The objective of the present study was to develop a discriminatory and reproducible accelerated release
testing method for naltrexone loaded parenteral polymeric microspheres. The commercially available
naltrexone microsphere product (Vivitrol®) was used as the testing formulation in the in vitro release
method development, and both sample-and-separate and USP apparatus 4 methods were investigated.
Following an in vitro drug stability study, frequent media replacement and addition of anti-oxidant in the
release medium were used to prevent degradation of naltrexone during release testing at “real-time”
(37°C) and “accelerated” (45°C), respectively. The USP apparatus 4 method was more reproducible than
the sample-and-separate method. In addition, the accelerated release profile obtained using USP apparatus
4 had a shortened release duration (within seven days), and good correlation with the “real-time” release
profile. Lastly, the discriminatory ability of the developed accelerated release method was assessed using
compositionally equivalent naltrexone microspheres with different release characteristics. The developed
accelerated USP apparatus 4 release method was able to detect differences in the release characteristics of
the prepared naltrexone microspheres. Moreover, a linear correlation was observed between the “realtime” and accelerated release profiles of all the formulations investigated, suggesting that the release
mechanism(s) remain the same under both conditions. These results indicate that the developed
accelerated USP apparatus 4 method has the potential to be an appropriate quality control tool for longacting naltrexone PLGA microspheres.
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3.1.Introduction
Biodegradable polymeric microsphere system based parenteral controlled release drug products have been
widely used for long-term controlled delivery of small molecule therapeutics as well as biologics such as
peptides and proteins owing to their various clinical advantages such as low dosing frequency and hence
improved patient compliance, as well as their ability to maintain effective therapeutic concentrations over
extended periods of time, thus enhancing product safety and efficacy [1, 2]. As the improved therapy of
these controlled release drug products is rooted in the optimum drug concentration/time profiles at the site
of action in the body, therefore, it is essential to understand drug release characteristics of these types of
drug products to ensure product performance and safety.
“Real-time” in vitro release testing is typically conducted to characterize drug release characteristics
under physiological conditions [3, 4]. However, “real-time” in vitro release testing of controlled release
formulations often runs over a long period of time ranging from weeks to months, or even years [5-8],
which if applied to batch release testing would result in reduced effective product shelf-life.
Consequently, there is a need to develop fast and reliable quality control tool(s) to assure product
performance as well as batch-to-batch reproducibility for consistent pharmacological effect. An
accelerated in vitro release testing method, which increases drug release rate and hence reduces the testing
duration, can aid in fast production batch release as well as speed up product development.
Various conditions such as high temperature [9], extreme pH [10, 11], organic solvent as well as
addition of surfactant [12], have been used to accelerate drug release from PLGA microspheres [13]. All
these approaches speed up the drug release rate via different mechanisms such as increased molecular
mobility of the drug as well as the polymer chains and increased water/media penetration, all of which
lead to fast drug diffusion and enhanced polymer degradation rate. It is known that drug release from
polymeric microspheres is mainly controlled by a combination of drug diffusion and polymer erosion
[14]. Selection of an appropriate accelerated approach depends on various factors such as the polymer
glass transition temperature [10, 15, 16], and the drug stability under various stress testing conditions
[17]. Ideally, accelerated in vitro release profiles should have 1:1 linear correlation with “real-time”
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release profiles after time scaling/shifting [14]. A 1:1 linear correlation shows that the exposure of
polymeric microspheres to such stress conditions does not alter the underlying drug release mechanism(s)
[12]. However, the use of extreme conditions to accelerate drug release may change the mechanism(s) of
drug release. Nevertheless, the accelerated drug release profiles should follow at least the same rank order
as the “real-time” release profiles [18]. Most importantly, the accelerated in vitro release testing method
should be able to differentiate any significant variation in drug release characteristics of formulations in
order to be used as a quality control tool, i.e. the method should show good discriminatory ability [19].
This is because minor manufacturing process changes may result in alteration of the release
characteristics [20].
Owing to the complexity of these controlled release drug products, currently there is no compendial
method available for parenteral polymeric microspheres. Various in vitro release testing methods have
been used to investigate “real-time” and accelerated in vitro release characteristics of parenteral
polymeric microspheres, including dialysis, sample-and-separate and USP apparatus 4 methods [9, 2123]. The sample-and-separate method is simple, and provides reasonably accurate assessment of in vitro
drug release, which makes it useful during the initial stages of product development. On the other hand,
the USP apparatus 4 (continuous flow through) method utilizes a compendial apparatus with well-defined
geometry and hydrodynamic conditions and hence, offers various advantages such as better
reproducibility [24]. The U.S. FDA has recommended that a dissolution method using USP apparatus 4,
and, if applicable, USP apparatus 2 (Paddle) or any other appropriate method, should be developed for
comparative in vitro release evaluation of such drug products. Accordingly, both sample-and-separate and
USP apparatus 4 methods were investigated in the present study. The aim of the present work was to
develop a reproducible and discriminatory accelerated in vitro release testing method for compositionally
equivalent

polymeric

microspheres

with

manufacturing

differences.

Naltrexone

(the

active

pharmaceutical ingredient in the commercial microsphere product Vivitrol®) was chosen as a small
molecule model therapeutic. Compositionally equivalent polymeric microspheres were prepared using
different manufacturing processes. Both sample-and-separate and USP apparatus 4 methods were
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investigated. Furthermore, the reproducibility and discriminatory ability of the developed accelerated
release method were assessed.

3.2.Materials and Methods
3.2.1. Materials
PLGA (7525 DLG7E, MW>100 kDa) was purchased from Evonik (Birmingham, AL). Anhydrous
naltrexone base was purchased from Mallinckrodt Pharmaceuticals (St. Louis, MO). Poly (vinyl alcohol)
(PVA, MW 30-70 kDa), trifluoroacetic acid (TFA), and benzyl alcohol (BA) were purchased from
Sigma-Aldrich (St. Louis, MO). Methylene chloride (DCM), ethyl acetate (EA), and dimethyl sulfoxide
(DMSO, ACS grade) were purchased from Fisher Scientific (Pittsburgh, PA). Milli-Q® water (Barnstead,
Dubuque, IA) was used for all studies. All other chemicals were obtained commercially as analyticalgrade reagents.

3.2.2. Methods
3.2.2.1.Preparation of naltrexone microspheres
PLGA with similar molecular weight as that in the commercial product Vivitrol ® was used to formulate
naltrexone microspheres using an oil-in-water (o/w) emulsion solvent extraction/evaporation technique.
Briefly, 250 mg of PLGA (7525 DLG7E) was dissolved in organic solvent (i.e. ethyl acetate or methylene
chloride). Naltrexone was dissolved in benzyl alcohol (30%, w/v) and added to the polymer solution. The
organic phase was added to a 1% (w/v) PVA solution pre-saturated with organic solvent used (to prevent
abrupt precipitation of the polymer during preparation), and an o/w emulsion was then prepared by
employing droplet size reduction techniques such as homogenization or magnetic stirring. The resultant
o/w emulsion was added to the aqueous phase and stirred at 220 rpm for 15 h to allow microsphere
solidification and solvent removal under vacuum at room temperature. Microspheres were then removed
from vacuum and sieved using two sieves, a 212 μm sieve on the top and 25 μm sieve on the bottom. The
microspheres retained on the 25 μm sieve were collected, washed using an aqueous ethanol solution (25%
(v/v), <5°C), and lyophilized.
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3.2.2.2.Characterization of physicochemical parameters of naltrexone microspheres
3.2.2.2.1. High performance liquid chromatography (HPLC) analysis
The quantification of naltrexone was conducted using a PerkinElmer HPLC system (series 200) with a
UV absorbance detector (PerkinElmer, Shelton, CT) set at 210 nm. The mobile phase was phosphate
buffer (10 mM, pH 6.6)/methanol (35/65, v/v) and the flow rate was 1 mL/min. A Zorbax ® C18 column
(150 x 4.6 mm, 5 μm; Agilent technologies) was used as the stationary phase. The sample injection
volume was 10 μL for drug loading determination and 50 μL for in vitro release testing sample analysis.
The chromatographs were analyzed using a PeakSimple™ Chromatography System (SRI instruments,
Torrance, CA).
3.2.2.2.2. Drug loading
The naltrexone microspheres (~4 mg) were weighed and transferred into 5 mL volumetric flasks. DMSO
(2.5 mL) was added into the volumetric flasks and the samples were sonicated until all particles were
dissolved. Methanol was used to dilute the sample. The solution was filtered (Millex ® HV, 0.22 μm
PVDF syringe filter) and the naltrexone concentration was determined with a validated HPLC assay.
Drug loading was calculated as:

% 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 =

𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑒𝑛𝑡𝑟𝑎𝑝𝑝𝑒𝑑
𝑥 100
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑚𝑖𝑐𝑟𝑜𝑠𝑝ℎ𝑒𝑟𝑒𝑠 𝑎𝑛𝑎𝑙𝑦𝑧𝑒𝑑

3.2.2.2.3. Particle size analysis
Particle size and particle size distribution of the naltrexone microspheres were measured using an
AccuSizer autodiluter, single particle optical sizing system (Nicomp, Santa Barbara, CA). Briefly,
microspheres were dispersed in a filtered 0.1% (w/v) PVA solution in water to ensure good dispersion for
the particle size analysis.
3.2.2.2.4. Differential scanning calorimeter (DSC) analysis
The glass transition temperatures (Tg) of the naltrexone microspheres were analyzed using a modulated
temperature differential scanning calorimeter (MTDSC) (TA Instruments Q2000). Briefly, experiments
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were performed in hermetically sealed pans using a 2°C/min heating rate and a modulation amplitude of
± 0.82°C with an 80 s modulation period. The weight of each sample was ~ 5-6 mg. The Tg was
determined as the glass transition midpoint in the reversing signal. The crystallinity of naltrexone was
also investigated.
3.2.2.2.5. Porosity
Porosity of the prepared naltrexone microspheres was determined using a Mercury Porosimeter (AutoPore
IV 9500, Micromeritics). Briefly, approximately 200 mg of the naltrexone microspheres were introduced
into the porosimeter and tested at a mercury filling pressure of 0.53 psi. Total intrusion volume, total pore
area as well as porosity (%) were recorded.

% 𝑝𝑜𝑟𝑜𝑠𝑖𝑡𝑦 = 1 −

𝑏𝑢𝑙𝑘 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
𝑥 100
𝑎𝑝𝑝𝑎𝑟𝑒𝑛𝑡 (𝑠𝑘𝑒𝑙𝑒𝑡𝑎𝑙)𝑑𝑒𝑛𝑠𝑖𝑡𝑦

3.2.2.3.In vitro drug degradation study
An exhaustive study was performed in order to understand whether naltrexone was stable under different
in vitro release testing conditions such as phosphate buffered saline with different pH (i.e. 4.5, 6.0, 7.4,
and 9.0), and temperature (i.e. 37°C and 45°C). 0.02% (v/v) Tween 20 and 0.02% (w/v) sodium azide
were added to the testing media since they are included in the FDA recommended dissolution medium
[25]. In addition, the effect of antioxidant (i.e. sodium ascorbate) on the prevention of drug degradation
was investigated.

3.2.2.4.“Real-time” in vitro release study
Vivitrol® was used as the testing microsphere drug product to develop suitable in vitro release testing
method(s) for naltrexone microspheres. Both sample-and-separate and USP apparatus 4 methods were
investigated. In the case of the sample-and-separate method, 10 mg of microspheres were suspended in 50
mL of phosphate buffered saline (PBS, 10 mM, pH 7.4) with 0.02% (v/v) Tween 20 and 0.02% (w/v)
sodium azide and incubated in a water shaker bath at 100 rpm at 37°C. At pre-determined time intervals,
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one mL of release samples were withdrawn and centrifuged at 3,000 rpm for 3 min. Supernatants
(0.9 mL) were filtered through 0.22 μm filters and analyzed via HPLC. Fresh medium (0.9 mL) was
mixed with the pellets (if any) and transferred back to the testing vessels. In the case of the USP apparatus
4 method, 10 mg of microspheres were mixed with glass beads (1 mm) and placed in the USP apparatus 4
dissolution cell. The method of mixing the microspheres and the glass beads was as previously reported
[14]. 50 mL of PBS (10 mM, pH 7.4) with 0.02% (v/v) Tween 20 and 0.02% (w/v) sodium azide was
circulated through the flow through cells at a flow rate of 8 mL/min at 37°C. At pre-determined time
intervals, 1 mL of samples were withdrawn and replenished with fresh media. The obtained samples were
analyzed via HPLC. The release medium was replaced with fresh release media every five days to avoid
drug degradation during testing. Media replacement during the release testing was taken into account in
the calculation of the fraction released. All drug release tests were conducted in triplicate, and the results
were reported as the mean % cumulative release±SD.

3.2.2.5.Accelerated in vitro release study
Extreme release testing conditions (such as high temperature and pH) were investigated in order to
develop a suitable accelerated in vitro release testing method. Due to the instability of naltrexone under
extreme pH conditions, an elevated temperature accelerated in vitro release method at 45°C was
developed. Similar in vitro release testing procedures as described in 2.2.4. were used. Sodium ascorbate
(SA) (0.0625%, w/v) was added to the release medium to avoid media replacement during accelerated in
vitro release testing.

3.2.2.6.Statistical data analysis
Statistical analysis was performed to evaluate significant differences between different microsphere
formulation characteristics using a paired student t-test. The level of significance was accepted
at p < 0.05.

3.3.Results and Discussion
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3.3.1. In vitro drug degradation study
It has been reported in the literature that naltrexone base is prone to pH and temperature
dependent oxidative degradation [26]. In order to select suitable media for in vitro release testing
of naltrexone microspheres, the stability of naltrexone under different release testing conditions
(such as different pH, and temperature) was investigated. As shown in Figure 1, naltrexone was
relatively stable (< 5% degraded over 30 days) at low pH (i.e. pH 4.5 and pH 6.0) at 37°C.
Whereas, naltrexone degradation was dramatically increased at higher pH (i.e. pH 7.4 and pH
9.0) at 37°C, particularly at pH 9.0 (~25% degraded by day 5). At pH 7.4, naltrexone appeared to
be relatively stable since at day 5 only ~ 3% degraded at 37°C. In addition, naltrexone
degradation was accelerated at pH 7.4 under elevated temperature (45°C) resulting in more than
10% degradation at day 5 (Figure 2). The degradation product was collected and analyzed using
LC-MS/MS. A peak with an m/z value of 374.14 was observed (data not shown), suggesting the
presence of an N-oxide product of naltrexone (C20H24NO6) (as shown in Figure 3). The basic
drug naltrexone deprotonates under alkaline conditions and therefore, the drug may be more
susceptible to electron loss and hence oxidative degradation. It was observed that the addition of
an antioxidant (0.0625% (w/v) sodium ascorbate) in the medium (PBS, pH 7.4) containing
0.02% (v/v) Tween 20 and 0.02% (w/v) sodium azide, can protect naltrexone against oxidation
up to 10 days at 37°C (~4% degraded by day 10) (data not shown). This suggested that 0.0625%
(w/v) sodium ascorbate may be used to prevent naltrexone degradation during elevated
temperature release testing at 45°C, whereas media replacement may be necessary for “realtime” release testing. Accordingly, “real-time” in vitro release testing of naltrexone microspheres
at 37°C was performed via frequent media replacement (every five days) to avoid oxidative drug
degradation at pH 7.4.
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Figure 1. Effect of pH on the stability of naltrexone at 37°C (n=3). All the media contain 0.02%
(v/v) Tween 20 and 0.02% (w/v) sodium azide.
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Figure 2. Effect of temperature on the stability of naltrexone in PBS buffer (10 mM, pH 7.4)
containing 0.02% (v/v) Tween 20 and 0.02% (w/v) sodium azide (n=3). (A) 37°C and (B) 45°C.
3.3.2. “Real-time” in vitro release testing of naltrexone microspheres
The commercially available naltrexone microsphere product Vivitrol® was used as the
testing formulation for the development of reproducible and discriminatory in vitro
release testing method(s). Since there is a lack of compendial in vitro release testing
methods available for parenteral microsphere drug products, the two most commonly
used methods (i.e. sample-and- separate and USP apparatus 4) for such products were
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Oxidation

Naltrexone
Molecular weight: 341
Molecular formula: C20H23NO4

Degradation Product
Molecular weight: 374
Molecular formula: C20H24NO6

Figure 3. Possible oxidative degradation pathway of naltrexone under the in vitro release testing
conditions investigated.
investigated. As shown in Figure 4, sustained naltrexone release from Vivitrol® with a very low
initial burst release (ca. 0.5%) was observed, indicating that most of the drug was possibly
entrapped inside the microsphere core during preparation. It was observed that more than 90%
naltrexone was released from Vivitrol® by day 35 at 37°C, which is consistent with naltrexone
release from Vivitrol® in vivo (over a period of 40 days) [27]. Since the release medium was
replaced every five days, no major degradation peak(s) in the HPLC chromatograms were
observed throughout testing, confirming that frequent media replacement can be implemented to
avoid naltrexone degradation in the release media (10 mM PBS, pH 7.4) containing 0.02% (v/v)
Tween 20 and 0.02% (w/v) sodium azide. Reproducibility of the “real-time” USP apparatus 4
method was also investigated. It can be seen from Figure 5 that the in vitro release profiles of
Vivitrol® (different batches, A and B) obtained at different testing dates overlapped, indicating
the USP apparatus 4 method was very reproducible under the “real-time” testing conditions
(37°C).
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Figure 4. In vitro release profile of Vivitrol® in 10 mM PBS (pH 7.4) containing 0.02% (v/v)
Tween 20 and 0.02% (w/v) sodium azide at 37ºC obtained using the USP apparatus 4 method
(n=3). The dissolution media was replaced every 5 days.

Cumulative Naltrexone Release (%)

100

80

60

40

Vivitrol®_Batch A

20

Vivitrol® _Batch B_Reproducility Test
0
0

5

10

15

20

25

30

35

40

Time (day)

Figure 5. In vitro release profiles of different batches of Vivitrol® in 10 mM PBS (pH 7.4)
containing 0.02% (v/v) Tween 20 and 0.02% (w/v) sodium azide obtained using the USP
apparatus 4 method (n=3) at 37ºC. The dissolution medium was replaced every 5 days.
In vitro release testing of the two batches of Vivitrol® (Batch A and B) was also performed
using the sample-and-separate method. As shown in Figure 6, less than 90% naltrexone release
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was observed by day 27. However, the in vitro release profiles of the two batches of Vivitrol®
differed from one another when the sample-and-separate method was used. Since sample
separation as well as media replacement via centrifugation was performed during release testing,
variable amounts of sample loss during sample collection as well as media replacement might
have occurred, thus resulting in irreproducible results. Although release media containing 0.02%
Tween 20 was used to facilitate microsphere wetting as well as to minimize aggregation,
microsphere aggregation was observed during testing. Compared to the sample-and-separate
method, no sample separation and hence microsphere loss occurred when the USP apparatus 4
method was used. In addition, the addition of glass beads in the USP apparatus 4 dissolution cells
minimizes microsphere aggregation, as well as facilitates laminar flow of the release medium
throughout the dissolution cells. Lastly, the USP apparatus 4 method is based on compendial
dissolution apparatus with well-defined geometry and hydrodynamic conditions, which can
facilitate inter-laboratory comparisons. Taken together, the USP apparatus 4 method appears to
be a suitable in vitro release testing method for naltrexone microspheres.
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Figure 6. In vitro release profiles of different batches of Vivitrol® in 10 mM PBS (pH 7.4)
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containing 0.02% (v/v) Tween 20 and 0.02% (w/v) sodium azide obtained using the sample-andseparate method at 37ºC (n=3). The dissolution medium was replaced every 5 days.
3.3.3. Accelerated in vitro release testing of naltrexone microspheres
Different strategies (such as extreme pH, and elevated temperature) have been utilized to
accelerate drug release from PLGA microspheres [9-11]. Elevated temperature conditions can
increase polymer erosion [14] as well as drug diffusion by increasing molecular mobility [28],
consequently resulting in accelerated drug release within a short period of time. However, it has
been shown in Figure 2 that elevated temperature (45°C) resulted in increased naltrexone
degradation. In order to develop a suitable fast quality control method for naltrexone
microspheres, both frequent media replacement (every 12 h) as well as the use of 0.0625% (w/v)
sodium ascorbate in the release medium (10 mM PBS, pH 7.4) without media replacement were
investigated using USP apparatus 4. As shown in Figure 7, naltrexone release from Vivitrol®
was dramatically accelerated at 45°C, and the release testing duration was significantly reduced
from 35-40 days (“real-time”, at 45°C) to around 6 days at 45°C in both cases. Moreover, the
addition of 0.0625% (w/v) sodium ascorbate in the release medium successfully prevented
naltrexone from degradation during accelerated release testing. The accelerated in vitro release
profile obtained in the release medium containing 0.0625% (w/v) sodium ascorbate without
media replacement was almost identical to that obtained with frequent media replacement. Based
on these results, 0.0625% (w/v) sodium ascorbate was added to the release media during the
elevated temperature accelerated release testing at 45°C. The reproducibility of the developed
accelerated USP apparatus 4 method was also investigated. As shown in Figure 8, in vitro
release profiles of Vivitrol® (Batches A and B) obtained at different testing dates almost
overlapped, indicating that the developed accelerated USP apparatus 4 method was reproducible.
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Figure 7. In vitro release profiles of Vivitrol® in 10 mM PBS (pH 7.4) containing 0.02% (v/v)
Tween 20 and 0.02% (w/v) with or without an antioxidant (sodium ascorbate) obtained using
USP apparatus 4 at 45°C (n=3). The medium without sodium ascorbate was replaced every 12 h
while the medium with sodium ascorbate was not replaced during testing.
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Figure 8. In vitro release profiles of different batches of Vivitrol® in 10 mM PBS (pH 7.4)
containing 0.02% (v/v) Tween 20, 0.02% (w/v) sodium azide and 0.0625% (w/v) sodium
ascorbate obtained using USP apparatus 4 at 45°C (n=3).
For sustained release PLGA microspheres, “real-time” release testing requires extended

53

periods of time, which may affect the time for batch release of product as well as delay the
product development process. Accordingly, an accelerated in vitro release method with good
correlation with “real-time” in vitro release is essential. As shown in Figure 9, the time-scaled
“real-time” release profile overlapped with the respective accelerated release profile obtained
using USP apparatus 4. A linear correlation between the fractions released under “real-time”
(time-scaled, scaling factor: 6.5) and accelerated conditions was observed for the USP apparatus
4 method with a regression coefficient (R2) above 0.99. This suggested that the drug release
mechanisms (the combination of polymer erosion and drug diffusion) at both temperatures may
be similar.
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Figure 9. In vitro release profiles of Vivitrol® in 10 mM PBS (pH 7.4) at 37 °C (time-scaled)
and at 45°C using the developed USP apparatus 4 method (n = 3). Insert figure shows linear
correlation between “real-time” (time-scaled, scaling factor: 6.5) (37°C) and accelerated (45°C)
fraction of naltrexone released.
It has been previously reported that manufacturing changes (such as solvent systems, and
emulsification processes) can affect microsphere physicochemical characteristics, which in turn
can affect their in vitro and in vivo performance [13]. Accordingly, it is essential to develop in
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vitro release testing methods that are capable of detecting changes in in vitro release
characteristics resulting from changes in the manufacturing process. The capability of the
developed accelerated USP apparatus 4 method to differentiate naltrexone microspheres with
manufacturing

differences

was

investigated.

Compositionally

equivalent

naltrexone

microspheres were prepared using different manufacturing processes. It can be seen in Table 1
that all the prepared naltrexone microspheres had similar drug loading (~29%, w/w), despite
different manufacturing processes. Since different particle size reduction techniques were used,
the prepared naltrexone microspheres had different particle size and particle size distribution.
Furthermore, the prepared naltrexone microspheres showed different porosity, indicating that
these microspheres may have different internal structures as a result of differences in the
dynamic solvent exchange processes during microsphere solidification. No significant
differences were observed in the Tg of the microspheres, and the physical mixture of the drug and
the PLGA polymer (ca. 42 °C). Due to the differences observed in their critical quality attributes
(such as particle size and porosity), these microsphere formulations possessed different “realtime” in vitro release characteristics [29]. The discriminatory ability of the developed elevated
temperature USP apparatus 4 method was assessed using these microsphere formulations with
different in vitro release characteristics.
Table 1. Physicochemical properties of naltrexone microsphere formulations (n=3)
Drug loading
Sample

Porosity

Solvent

D50 (Mean ± SD) (μm)
(%, w/w)

(%, w/w)
Population
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Volume

Formulation 1

DCM&BA

28.74±1.64

49.83

42.93±9.69

121.11±3.61

Formulation 2

EA&BA

29.7±1.11

58.32

53.93±5.27

105.49±8.63

Formulation 3

EA&BA

29.57±1.75

65.08

44.32±2.07

68.56±1.52

Vivitrol®

-

33.50±1.43

50.21

58.46±6.01

108.49±1.52

* BA: benzyl alcohol, EA: ethyl acetate, DCM: methylene chloride
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Figure 10. In vitro release profiles of the prepared naltrexone microspheres in 10 mM PBS (pH
7.4) containing 0.02% (v/v) Tween 20, 0.02% (w/v) sodium azide and 0.0625% (w/v) sodium
ascorbate using USP apparatus 4 at 45°C (n=3).
As shown in Figure 10, the accelerated USP apparatus 4 method was capable of
discriminating the prepared compositionally equivalent naltrexone microspheres with
manufacturing differences. Drug release from the prepared microspheres reached a plateau
around day 6 (Formulations 1 and 2) and day 4 (Formulation 3). Accelerated release profiles of
all the prepared naltrexone microsphere formulations followed the same rank order as their “realtime” release profiles. Release testing duration was reduced from 40 days (Formulations 1 and 2)
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and 30 days (Formulation 3) to within 6 days under accelerated conditions. The fraction released
under accelerated testing conditions were compared with that under “real-time” testing
conditions (after time scaling) for all the prepared naltrexone microspheres. As shown in Figure
11, the time-scaled “real-time” release profiles overlapped with their respective accelerated
release profiles for all the prepared naltrexone microsphere formulations investigated. A linear
correlation was obtained between the time-scaled “real-time” and accelerated fraction released
with a regression coefficient (R2) of >0.98. This suggested that the release mechanisms at both
temperatures may be similar. These results demonstrated the developed accelerated USP
apparatus 4 method is both discriminatory and reproducible. Accordingly, it can be used as a
suitable fast quality control tool for naltrexone microspheres.
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Figure 11: In vitro release profiles of Formulations 1, 2 and 3 in 10 mM PBS (pH 7.4) at 37°C
(time-scaled) and at 45°C using the USP apparatus 4 method (n = 3). Insert figures show linear
correlations between “real-time” (time-scaled) (37°C) and accelerated (45°C) fractions of
naltrexone released. (A) Formulation 1; (B) Formulation 2; and (3) Formulation 3.
3.4. Conclusion
A reproducible accelerated release testing method with discriminatory ability was developed using USP
apparatus 4 for compositionally equivalent naltrexone loaded polymeric microspheres with manufacturing
differences for the first time. The degradation of naltrexone was prevented using frequent media
replacement and anti-oxidant containing media during “real-time” and accelerated release testing,
respectively. The accelerated in vitro release profiles of naltrexone microspheres correlated well with
their respective “real-time” release profiles, indicating that the drug release mechanism(s) may be similar
under both release testing conditions. Overall, the developed accelerated USP apparatus 4 release testing
method has demonstrated the potential of being a fast quality control tool that will assure the product
performance as well as assist the product development of parenteral naltrexone polymeric microspheres.
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Chapter 4

Development of Level A In Vitro-In Vivo Correlations for Peptide Loaded PLGA
Microspheres

Abstract:
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Peptide loaded PLGA microsphere products are more complex in terms of manufacturing,
drug release characteristics as well as release mechanism compared to small molecule loaded
PLGA microsphere products. This is due to the complex structure of peptides, their
hydrophilicity, charged state, large size and potential for instability. Moreover, therapeutic
peptides are highly potent and therefore, any unintended change in the microsphere release
profile may lead to undesirable side effects and toxicity. Accordingly, the objectives of the
present work were: 1) to evaluate the impact of minor manufacturing changes on the quality and
performance of peptide microspheres; and 2) to investigate the feasibility of developing Level A
in vitro-in vivo correlations (IVIVCs) for peptide microspheres. Compositionally equivalent
leuprolide acetate (LA) microspheres prepared with minor manufacturing changes (solvent
system/homogenization speed) showed significant differences in their physicochemical
properties (such as pore size, total porosity, particle size and surface distribution of peptide on
the prepared microspheres). This, in turn, resulted in significant alteration in the release
characteristics. Peptide-polymer interaction, in vitro degradation and microsphere morphology
studies were conducted to facilitate understanding of the differences in the drug release
characteristics. A rabbit model was used to determine the pharmacokinetic profiles of all the
prepared formulations. The obtained in vivo release profiles showed the same rank order as the in
vitro release profiles but with low burst release and overall faster in vivo release rates. The low in
vivo burst release is considered to be due to the masking effect of the absorption phase from the
intramuscular site, and this complicated the development of an IVIVC. Despite these challenges,
an affirmative Level A IVIVC over the entire release profile was successfully developed for
peptide microspheres for the first time. This work highlights the feasibility of developing
IVIVCs for complex parenteral drug products such as peptide microspheres. In conclusion, these
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results indicate the sensitivity of peptide release, and hence, the safety and efficacy of highly
potent peptide microspheres, to minor manufacturing changes. Accordingly, development of
IVIVCs for such complex drug products is highly desirable.

4.1. Introduction:
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As per the U.S. FDA guidance1, an in vitro-in vivo correlation (IVIVC) is a predictive
mathematical model describing the relationship between an in vitro property (e.g. rate or extent
of drug release) of a dosage form and a relevant in vivo response (e.g. plasma drug
concentration or amount of drug absorbed vs time). Despite the successful commercialization of
various types of extended release microsphere drug products and their increasing popularity in
the past few decades2, there have been few reports on the development of IVIVCs. Most of the
reported literature is “proof-of-concept” research demonstrating the possibility of developing
IVIVCs for microspheres3-9. This is because the development of IVIVCs for long-acting
polymeric microspheres is very challenging principally due to their complex drug release
characteristics and the lack of standard bio-predictive in vitro release testing methods10-13 as well
as the lack of regulatory guidance. Despite these challenges, our group has recently developed a
1:1 linear correlation, Level A1 IVIVC (the most affirmative type of IVIVC with the potential to
be used to obtain biowaivers) for microsphere drug products containing a variety of small
molecules 14,15. These microsphere products had tri-phasic and bi-phasic in vitro release profiles
with and without a lag phase, respectively but with low burst release (i.e. Type-I and Type-II
release profiles, Figure 1). Figure 1 is representative of the different types of release profiles
typically observed with PLGA microsphere products. Compared to the release Types I and II, the
release Type III PLGA microspheres have a high burst release followed by slow and continuous
release. To further explore the concept and achieve a comprehensive understanding of the
development of IVIVCs for PLGA microspheres, it was considered essential to investigate the
feasibility of developing IVIVCs for the release Type III microsphere drug products. Typically,
microspheres containing hydrophilic drug molecules (peptides and small molecules) tend to have
higher burst release (Type III). Moreover, peptides have complex structure, charged state and
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larger size compared to small molecules and therefore, peptide microspheres have more complex
release mechanisms compared to small molecule microspheres. This may result in variations in
drug release under in vivo conditions compared to in vitro conditions, complicating the
development of IVIVCs for peptide microspheres. There have been no reports to date on the
development of Level A IVIVCs for compositionally equivalent peptide microspheres.
Typical PLGA micropsheres release profiles
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Figure 1: Schematic representation of
typically observed drug release profiles of
PLGA microspheres.
Type I – Low burst release phase followed
by lag phase and secondary release phase
Type II – Low burst release phase
followed by secondary release phase
Type III – High burst release phase
followed by secondary release phase

Peptide microsphere products are also more complex in terms of manufacturing as a result of
the hydrophilic nature, large size and relative instability of peptides. Moreover, due to
differences in the physicochemical properties of peptides and small molecules, the impact of
minor manufacturing changes on the quality and performance of peptide microspheres may be
more or less significant compared to small molecule microspheres. In addition, therapeutic
peptides are highly potent and hence, any unintended minor changes in the release profiles may
lead to undesirable side effects and toxicity. Accordingly, it is crucial to understand the impact of
minor manufacturing changes on the physicochemical properties (quality) and release
characteristics (performance) of compositionally equivalent peptide microsphere drug products.
The therapeutic peptide, leuprolide acetate (LA) was chosen as the model peptide since it is
commercially available in the microsphere drug product, Lupron Depot® (RLD). This product is
off patent, and accordingly generic companies may be actively seeking to develop generic
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versions. Therefore, it is critical for the industry as well as the regulatory authorities to
understand the impact of manufacturing differences on the quality and performance of LA
microsphere drug products. An additional aspect is that this product is prepared using a low
molecular weight (M.wt.) PLGA16-17, and there have been no studies investigating the impact of
minor manufacturing changes on the performance of such microspheres. Since this product
contains positively charged peptide and the polymer is negatively charged at pH 7.4, there is
potential for charge–charge interaction to affect drug release18. Hence, this study will provide
important insights into the impact of manufacturing differences on the release mechanism of
such complex microsphere products.
The objectives of the present work were to evaluate the impact of minor manufacturing
changes on the physicochemical properties and drug release characteristics as well as to
investigate the feasibility of developing a Level A IVIVC for compositionally equivalent
parenteral microsphere products containing a peptide drug. Leuprolide acetate (LA) was chosen
as the model peptide. Four compositionally equivalent LA microspheres were prepared with
manufacturing differences and characterized for various physicochemical properties (such as
drug loading, particle size, porosity, morphology and M.wt.). The in vitro release characteristics
of the prepared LA microsphere formulations and the RLD product were determined using the
developed in vitro release testing method. The pharmacokinetic profiles of the LA microspheres
were investigated using a rabbit model. The in vivo profiles were deconvoluted using the LooRiegelman method and compared with the respective in vitro release profiles to investigate the
possibility of establishing an IVIVC.
4.2. Material and Methods
4.2.1. Materials
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PLGA (Resomer® Select 7525 DLG 2CA) was purchased from Evonik (Birmingham, AL).
Leuprolide Acetate (LA) and reference standard (i.e. LHRH Acetate salt) were purchased from
Bachem Americas, Inc (Torrance, CA). Poly (vinyl alcohol) (PVA, M.wt. 30-70 kDa) and
trifluoroacetic acid (TFA) were purchased from Sigma-Aldrich (St. Louis, MO). HPLC-grade
Methylene chloride (DCM), methanol (MeOH), acetonitrile (ACN) and ACS-grade dimethyl
sulfoxide (DMSO) were purchased from Fisher Scientific (Pittsburgh, PA). LC-MS grade 0.1%
v/v formic acid in water, 0.1% v/v ammonium acetate in water and acetonitrile were purchased
from VWR (Radnor, PA). Milli-Q® water was used for all studies. All other chemicals were
obtained commercially as analytical-grade reagents.
4.2.2. Preparation of leuprolide acetate microspheres
PLGA (M.wt ~15KDa) with a similar molecular weight as that used in the commercial
product, Lupron Depot®, was used to formulate compositionally equivalent LA microsphere
formulations using different manufacturing processes. Briefly, 200 mg of PLGA was dissolved
in methylene chloride (45%, w/v). LA is poorly soluble in methylene chloride and accordingly, a
co-solvent (such as methanol and DMSO) was used to facilitate the dissolution of LA. The LA
solution was then added to the polymer solution to form the organic phase and mixed via
vortexing. The organic phase containing both the polymer and drug was then dispersed into a
0.35% (w/v) PVA solution (0.22 µm membrane filtered) to form an oil-in-water (o/w) emulsion
using a homogenizer ((IKA® Works, Inc.) set at 14,000 rpm for 10 seconds followed by 13,000
rpm for 90 seconds. Leuprolide acetate microspheres with large particle size were prepared using
a lower emulsification/size reduction force (homogenizer set at 9000 rpm for 10 seconds
followed by 8000 rpm for 90 seconds). The resultant o/w emulsion was stirred at 400 rpm for 3 h
under vacuum at room temperature to allow microsphere solidification and solvent evaporation.
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The resultant microspheres were collected, washed using distilled water and dried via
lyophilization.
4.2.3. Characterization of LA microspheres
4.2.3.1. High performance liquid chromatography (HPLC) analysis
The quantification of LA was conducted using an Agilent HPLC system (series 1200) with a
UV absorbance detector set at 220 nm (release test samples)/280 nm (drug loading test samples).
The mobile phase consisting of 0.1% (v/v) tri-fluoroacetic acid in water (A) and acetonitrile (B)
was used for separation of LA through gradient elution (Table 1) at 30°C. A Kinetex® EVO C18
column (250 x 4.6 mm, 5μm, 100Å, Phenomenex) was used as the stationary phase. The sample
injection volume was 20 µL for drug loading and 50 µL for in vitro release testing sample
analysis. The chromatographs were analyzed using an Agilent OpenLAB chromatography data
system.
Table 1. HPLC gradient elution method for leuprolide acetate analysis
Time (min)
0
10
12
15

Flow rate
(mL/min)
1.0
1.0
1.0
1.0

%A

%B

90
80
90
90

10
20
10
10

4.2.3.2. Drug loading
The LA microspheres (~5 mg) were weighed and transferred into 10 mL volumetric flasks.
DMSO (2 mL) was added into the volumetric flasks and the samples were sonicated until all
particles were dissolved. Methanol was used to dilute the samples. The solutions were filtered

70

(Millex® HV, 0.22 µm PVDF syringe filter) and the LA concentrations were determined via the
validated HPLC assay as described above. All the measurements were conducted in triplicate and
the results are reported as the mean ± SD. Drug loading was calculated as:

Drug Loading (%) =

weight of drug entrapped
× 100
weight of microspheres analyzed

4.2.3.3. Particle size and size distribution
Particle size and particle size distribution of the LA microspheres were measured using an
AccuSizer autodiluter particle sizing system (Nicomp, Santa Barbara, CA). Briefly, the
microspheres were dispersed in a filtered 0.1% (w/v) PVA solution in water to ensure good
dispersion, and then particle size analysis was conducted. All the measurements were conducted
in triplicate and the results are reported as the mean size ± SD.
4.2.3.4. Morphology
The morphology of the LA microspheres was analyzed using scanning electron microscopy
(SEM). Briefly, dry microspheres were mounted on carbon taped aluminum stubs and sputter
coated with gold under an argon evaporator at high vacuum. The samples were then observed
using SEM (NanoSEM 450, Nova).
4.2.3.5. Porosity
The porosity of the LA microspheres was determined using a Mercury Porosimeter
(AutoPore IV 9500, Micromeritics). Briefly, approximately 200 mg of LA microspheres were
introduced into the porosimeter and tested at a mercury filling pressure starting at 0.53 psi. Total
% porosity and average pore diameter were recorded.
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Porosity (%) = (1 −

Bulk density
) × 100
Apparent (skeletal)density

4.2.3.6. Differential scanning calorimeter (DSC) analysis
The glass transition temperatures (Tg) of the LA microspheres were analyzed using a
modulated temperature differential scanning calorimeter (MTDSC) (TA Instruments Q2000).
Briefly, weighed quantity (~ 5-6 mg) of each sample was transferred to standard aluminum pans
and sealed with aluminum lids. The DSC experiment was performed using a 2°C/min heating
rate and a modulation amplitude of ± 0.82°C with an 80 s modulation period. All samples were
subjected to a heat/cool/heat cycle. The results were analyzed by using TA analysis software, and
the Tg was determined as the glass transition midpoint in the reversing signal.
4.2.3.7. Molecular Weight
The molecular weight of the microspheres was determined by gel permeation chromatography
(GPC; Waters) with an evaporative light scattering detector (ELSD). The mobile phase was
tetrahydrofuran (THF) with a flow rate of 2 ml/min at 40◦C. Samples were dissolved in THF at a
concentration of 1 mg/mL and filtered (0.45 μm filter, Millipore, USA) before injection into the
GPC system. The data collection and analysis were performed using Waters Millenium software.
Polystyrene standards (2000, 900, 824, 400, 200, 110, 43, 18.80, 17.60, 6.93, 2.61, 0.98 kDa)
were used for calibration and weight average molecular weights (M.wt.) were calculated. All
measurements were conducted in triplicate and the results are reported as the mean ± SD.
4.2.4. Peptide-polymer interaction study:
FT-IR spectroscopy was performed using a Nicolet FTIR (iS5 FTIR, Thermo Scientific)
spectrometer attached with an attenuated total reflectance (ATR) accessory. Briefly, the samples
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were placed on the crystal window (Germanium) and compressed lightly using a pressure clamp.
Spectra were recorded over a range of 400–4000 cm-1 with a resolution of 4 cm-1, for 128 parallel
scans and evaluated for any shifts in the functional peaks. Data analysis was performed using
Omnic software (Thermo Nicolet Corporation). The physical mixture was prepared using an
accurately weighted quantity of drug and polymer in a ratio same as that of the drug loading of
prepared LA micrspheres (Polymer: drug, 92:8 % w/w).
4.2.5. In vitro release studies
In vitro release testing of the LA microspheres was conducted using a developed sample-andseparate method at 37°C. Briefly, 6 mg of microspheres were dispersed in 1 mL of phosphate
buffered saline (PBS containing 0.02% (v/v) Tween 20 and 0.02% (w/v) sodium azide, 33mM,
pH 7.4) in low protein binding eppendorf tubes mounted on a rotator set at 100 rpm and
incubated at 37 °C. At pre-determined time intervals, release media was collected and
centrifuged at 3,000 rpm for 3 min. Supernatants (0.3 ml) were filtered through 0.22 μm filters
and analyzed via HPLC. The release media was replaced with fresh media at each sampling time
point. Media replacement during release testing was taken into account in the calculation of the
% cumulative release. All drug release tests were conducted in triplicate and the results are
reported as the mean % cumulative release ± SD.
4.2.6. In vitro degradation studies
An exhaustive in vitro degradation study of the LA microspheres was conducted similar to
the in vitro release testing method. At pre-determined time points, microsphere samples
incubated under release testing conditions were collected, washed, lyophilized and evaluated for
polymer molecular weight using gel permeation chromatography (GPC) and morphology using
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scanning electron microscopy (SEM) as mentioned above.
4.2.7. In vivo release studies
The in vivo release characteristics of the LA microspheres were investigated using a rabbit
model. Briefly, male rabbits (New Zealand White, n = 6) weighing approximately 3 to 4 kg were
randomly assigned to each treatment group i.e. formulation. The LA microspheres were
suspended in the diluent used for dispersion of the commercial product Lupron Depot® and
injected into the rabbit hind leg thigh muscles at a dose of 2.14 mg/kg. In addition, a
pharmacokinetic study of the LA solution in saline (dose: 0.025mg/kg, i.v.) injected via the
intravenous route was conducted (n = 6) to determine the PK parameters of LA in rabbit. Blood
samples were collected from the marginal ear veins at predefined time intervals. The collected
blood samples were centrifuged at 14,500 rpm for 5 min to separate out the plasma. The plasma
was collected and stored at -80°C until analysis. The animal study protocol was reviewed and
approved by the University of Connecticut's Institutional Animal Care and Use Committee
(IACUC) prior to the beginning of the experiments.
4.2.8. Plasma sample analysis
LA ((Des-Gly10, D-Leu6, Pro-NHEt9)-LHRH, M.wt. 1209.42 Da) was extracted from plasma
samples using a protein precipitation extraction method. LHRH ((Des-Gly10, D-Ala6, ProNHEt9)-LHRH, M.wt. 1167.34 Da) acetate salt was used as the internal standard (IS). Briefly,
100 μl of plasma samples were mixed with either 100 μl of LA solution in diluent (0.1% formic
acid in water: acetonitrile (90:10, %v/v)) for the preparation of calibration standards (1, 2.5 5, 10,
15, 20 and 30 ng/ml) or 100 μl of diluent for study samples. All the samples were then spiked
with 20 μl of the IS solution (200 ng/ml in methanol). Ice-cold acetonitrile was then added in a
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stepwise fashion (two-steps, each of 500 μl) to the pre-treated plasma samples and vortex-mixed
for 10 minutes at 2,500 rpm followed by centrifugation at 14,500 rpm (4°C) for 8 minutes. The
supernatants were transferred to the low-protein binding polypropylene (PP) centrifuge tubes and
dried under nitrogen at 40°C. The dry residues were then reconstituted in 100 μl of diluent (0.1%
formic acid in water/acetonitrile, 90:10 %v/v). 25 μl of the reconstituted solution was used for
LC-MS/MS analysis. Please note that during the entire preparation process, plasma samples were
processed in the ice bath before the collection of supernatant samples for drying.
The LC-MS/MS system consisted of an Agilent HP-1100 LC system and a TSQ Quantum
Ultra Mass Spectrometer (Waters) with an electrospray ionization (ESI) ion source.
Chromatographic separations were carried out on a Kinetex EVO C18 column (50 x 2.1 mm, 2.6
μm, 100 Å) through gradient elution (Table 29) at 35°C. The following MS detection parameters
were used: 4400 V electrospray voltage, 320°C capillary temperature, and 35 V collision energy.
Detection of ions was conducted in the positive-ion selected reaction monitoring mode with the
following transitions in a single reaction monitoring (SRM) mode: m/z 605.5 to 249.1 for
leuprolide acetate, and 584.67 to 249.1 for the IS. The injection volume was 25 μl. The data
acquisition was ascertained by Xcalibur software. Calibration curves were established on each
day when analysis was conducted and showed good linearity with correlation coefficients > 0.99.
The lowest limit of quantification (LLOQ) for LA was 1 ng/mL and the mean recovery of plasma
samples from low to high concentrations of LA was more than 90%. The inter- and intra-day
variations of the three different concentrations of naltrexone (1, 10, and 30 ng/mL) were less
than 15%.
Table 2. HPLC gradient method for the determination of leuprolide acetate content in rabbit
plasma.
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Time
(min)
0
5
8
9
12

Flow rate
(ml/min)
0.3
0.3
0.3
0.3
0.3

0.1% formic Acid/0.1% ammonium
acetate (21/, v/v), %
95
40
40
95
95

ACN, %
5
60
60
5
5

4.2.9. Pharmacokinetic (PK) analysis and the development of an IVIVC
The development of IVIVC for the prepared LA microspheres was performed using a two
stage deconvolution approach following the same principles as detailed in the U.S. FDA
guidance on the development of IVIVC for extended release oral dosage forms 1. Briefly, the in
vivo plasma profiles of LA microspheres were deconvoluted using the Loo-Riegelman
method 12,19. Standard errors are not shown in the deconvoluted in vivo absorption profiles
because the average plasma concentration values were used. The fraction absorbed in vivo was
calculated as below:
𝐶𝑝 + 𝐶𝑡 + 𝐾10 (𝐴𝑈𝐶)𝑡0
𝐴𝑏
=
𝐴𝑏∞
𝐾10 (𝐴𝑈𝐶)∞
0
Cp, Ct, K10, and AUC are the drug concentration in the central compartment (plasma),
apparent tissue compartment concentration, elimination rate constant and area under the plasma
vs time curve, respectively. The distributive and elimination micro rate constants (k12, k21 and
k10) that are necessary for calculating Ct, and the total fraction absorbed at time t, were calculated
using a two compartment model, PK analysis tool, WinNonlin® 6.4 (Pharsight, Certara
Corporation, St.Louis, USA) from the plasma concentrations vs time profiles of LA solution after
single intravenous administration in rabbits. Similarly, PK parameters of all the LA microsphere
formulations were determined using non-compartmental analysis. The development and
validation of the IVIVC for the LA microspheres were performed using the IVIVC toolkit,
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WinNonlin® 6.4 (Pharsight, Certara Corporation St.Louis, USA).
4.2.10. Statistical data analysis
Statistical analysis was performed to evaluate significant differences between different
microsphere formulations using a paired student t-test. The level of significance was accepted
at p < 0.05.
4.3. Results and Discussion:
4.3.1. Physicochemical properties of the LA microspheres
Four LA microsphere formulations (i.e. F1, F2, F3 and F4) with Q1/Q2 equivalency were
prepared with minor manufacturing changes (such as cosolvents and homogenization speed) and
evaluated for differences in physicochemical properties, if any. The RLD product (Lupron
Depot® (one month)) was used as a control. As shown in Table 3, the drug loading of the RLD
product was around 7% (w/w) and all the prepared LA microsphere formulations had similar
drug loading of around 8% (w/w). This shows that the prepared LA microsphere formulations
were Q1/Q2 equivalent despite minor changes in the manufacturing process.
Table 3. Drug loading of the RLD and the LA microspheres prepared with minor manufacturing
changes.
Sample

Preparation Parameters

Drug Loading (%, w/w)

RLD

-

6.88±0.77

F1

Homogenization (DCM/methanol: 2.6/1,
w/w)

8.36±0.30

F2

Homogenization (DCM/methanol: 2.6/1,
w/w) (large particle size)

8.55±0.08

F3

Homogenization (DCM/DMSO: 3.7/1, w/w)

8.47±0.14
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Homogenization (DCM/DMSO: 3.7/1, w/w)
(large particle size)

F4

8.14±0.01

The mean particle size and size distribution of the prepared LA microspheres and the RLD
product were evaluated. As shown in Figure 2, all the prepared LA microsphere formulations
had larger particle size in terms of volume distribution and smaller or equal particle size in terms
of population distribution when compared to the RLD product. This, in turn, indicates a wide
size distribution (Figure 2B) in all the prepared microsphere formulations compared to the RLD
product. Moreover, formulations F1 and F3, prepared using similar homogenization speeds and
time, did not show significant differences in the particle size despite the use of different solvent
systems. This indicates that the impact of the solvent system on droplet size during
emulsification and of solvent evaporation rate during microsphere solidification on the final
particle size was not significant (p>0.05). However, formulations F2 and F4 had a larger mean
particle size in terms of volume distribution compared to formulations F1 and F3 prepared using
the same solvent system (Figure 2). This is due to the use of lower homogenization speed during
the emulsification process20,21.

120.00

D50 Value

A

7.00
6.00

100.00

Particle Size (um)

Span Value

B

5.00

80.00

4.00
60.00

3.00
40.00

2.00

20.00

1.00

0.00
RLD

F1

Population Distribution

F2

F3

0.00

F4

RLD

F1

Population Distribution

Volume Distribution

F2

F3

F4

Volume Distribution

Figure 2. Particle size and size distribution of the RLD product and LA microsphere
formulations prepared using minor manufacturing differences. (A) D50 value; and (B) Span
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value. All values are expressed as mean ± SD (n=3).
As shown in Figure 3A, some irregular shapes (indicated by the blue arrow) and a highly
porous polymer matrix (indicated by the red arrows) were observed for the RLD product. On the
other hand, the prepared LA microspheres showed a spherical shape with a smooth surface
(Figures 3B to 3E). Compared to formulations F1 and F2, formulations F3 and F4 showed a
more porous structure, which may be due to the different solvent systems used in processing.
Different solvent systems also lead to changes in the polymer precipitation rate. For example,
PLGA is more soluble in DCM/DMSO compared to DCM/methanol. Moreover, DMSO has a
higher boiling point and hence, will be removed slowly compared to methanol. Taken together,
these differences will lead to relatively slower solidification into microspheres for formulations
F3 and F4 compared to formulations F1 and F2, allowing more dynamic solvent exchange and
entrapment inside the microspheres. The removal of the entrapped solvents during drying will
create pores and hence, formulations F3 and F4 have more porous structures compared to
formulations F1 and F2.
RLD

50 μm
μm

5 μm

50 μm

10 μm

100 μm

20 μm

F4

200 μm

10 μm

100 μm

E

F5

20 μm

F

Figure 3. SEM images of the RLD product and leuprolide acetate microsphere formulations.
Symbol: The green arrow points to the irregular shapes of microspheres and the red arrows
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point to pores in the microsphere matrix.
The observed differences in the porous structure of the prepared microsphere formulations
were further confirmed and quantified by evaluation of the % porosity of the LA microsphere
formulations. As shown in Table 4, overall differences in the total % porosity of the
formulations were observed with F3 being the most porous and F2 being the least porous/more
dense formulation. In agreement with the morphological characteristics (Figure 2), formulations
F3 and F4 had relatively higher % porosity compared to formulations F1 and F2.
Since LA is a peptide of relatively higher molecular weight/larger size compared to small
molecules, it is reported that the pore diameter can also be a critical parameter controlling
diffusion out of microspheres into the release medium22. Accordingly, the average pore diameter
of the prepared LA microsphere formulations was investigated. As shown in Table 4, significant
differences in the average pore diameter of all the prepared formulations were observed with F2
having the smallest pore diameter and F3 having the largest pore diameter. The pore diameters of
formulations F1 and F2 were smaller than F3, which shows that the differences in the solvent
systems leads to differences in the pore diameter. In addition, despite the use of the same solvent
systems, the pore diameters of formulations F2 and F4 (smaller particle size microspheres) were
smaller than those of formulations F1 and F3 (larger particle size microspheres), respectively.
Similarly, the % porosity of formulations F2 and F4 was smaller than that of formulations F1 and
F3. These results indicate that particle size, in addition to the solvent system, has the potential to
alter the % porosity and pore diameter. It has been reported that faster solvent removal and
polymer precipitation leads to the formation of large pores23. Since diffusion distance will be
relatively shorter in small particles compared to larger particles, solvent exchange and solvent
removal will be faster for small particles compared to large particles.
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Table 4. Physicochemical properties of the prepared leuprolide acetate microsphere formulations
Formulation

Porosity
(%)

Avg. Pore
Diameter
(nm)

Tg (°C)

Molecular Weight (D)
(Mean ± SD)

F1

57.06

814.5

44.1

13245±173

F2

52.65

712.7

45.32

13406±41

F3

61.01

964

44.78

13541±22

F4

56.48

814.1

45.27

13550±60

As shown in Table 4, no significant differences in the Tg and polymer molecular weight of
the prepared LA microsphere formulations were observed for the minor manufacturing changes
investigated. However, the physicochemical properties of LA microspheres (such as particle size,
morphology, pore size, and % porosity) are sensitive to the minor manufacturing differences.
4.3.2. In vitro release characteristics of the LA microspheres
The in vitro release testing method was developed by screening different methods and
conditions (such as membrane dialysis vs sample and separate methods, buffer strength, media
replacement), with the aim to achieve 100% cumulative drug release as well as to maintain
peptide stability throughout the release study (data not shown). As shown in Figure 5A, 100%
drug release was achieved using the sample-and-separate in vitro release testing method. In
addition, the method had good reproducibility with less than 5% RSD at all time points (Figure
5A). As shown in Figure 5B, the in vitro release method was also able to discriminate changes
in the drug release characteristics of the LA microsphere formulations prepared using minor
manufacturing changes as well as the RLD product. Overall, all formulations appeared to follow
biphasic release characteristics with an initial burst release phase followed by an apparent zeroorder slow release phase over a period of at least 40 days.
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Differences in the drug release profiles, especially the burst release phase (from 10% to 39%
in 24 h) were observed for the formulations. Variable burst release is a result of differences in the
amount of surface associated drug, which may be due to one or the combination of the following
factors: 1) higher solubility of PLGA in DCM/DMSO compared to DCM/MeOH; and 2) slower
evaporation of DMSO compared to MeOH. These two factors result in slower microsphere
solidification and hence, more drug diffusion onto the surface of formulations F3 and F4
compared to F1 and F2. In addition, the higher solubility of LA in DMSO compared to MeOH
leads to greater accumulation of drug onto the surface of formulations F3 and F4 during solvent
exchange. Moreover, formulations F1 and F3 have small particle size compared to formulations
F2 and F4, resulting in the higher surface area to volume ratio and hence, a greater amount of
surface associated drug leading to higher burst release.
In addition to the burst release phase, differences in the release rate of all the LA
microspheres were observed over the initial 15-day period (Figure 4B). Formulation F3 had the
highest % porosity with the largest average pore diameter (Table 4) leading to greater peptide
diffusion and hence, a faster release rate compared to other formulations. Whereas formulation
F2, which exhibited the lowest porosity with the smallest average pore diameter (Table 4),
showed the slowest release rate. Moreover, formulations F2 and F4, which have larger particle
size and hence greater diffusion distance, exhibited slower release than formulations F1 and F3.
The RLD product, which is prepared using a gelatin based double emulsion method showed
higher burst release than all the prepared formulations. This may be due to the smaller particle
size (Figure 2) of RLD compared to the prepared formulations leading to higher amount of
surface associated drug. Moreover, the release profile of the RLD was tri-phasic, which may be a
result of the presence of gelatin.
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Sample-and-Separate Method, 37ºC

Cumulative Leuprolide Acetate Released (%)

105

Figure 4A. In vitro release profiles of
different batches of formulation F1 obtained
on different testing dates using the sampleand-separate method at 37°C (n=3). The
medium (33 mM PBS contaning 0.02% w/w
sodium azide and Tween 20, pH 7.4) was
replaced every two to three days.
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Figure 4B. In vitro release profiles of
compositionally
equivalent
LA
microspheres prepared with minor
manufacturing changes and the RLD
product obtained using the sample-andseparate method at 37°C (n=3). The
medium (33 mM PBS contaning 0.02%
w/w sodium azide and Tween 20, pH 7.4)
was replaced every two to three days.

Peptide polymer interaction study:
To further understand the impact of manufacturing differences on the drug release characteristics
and the underlying release mechanism(s) of the prepared LA microspheres, peptide-polymer
interactions as well as microsphere in vitro degradation were investigated.
It has been reported18 that LA is a positively charged peptide at neutral or lower pH, with the
potential to interact with the negatively charged carboxylic acid end groups in PLGA (pKa
~3.8)24. This can result in the adsorption of LA within the microspheres PLGA matrix leading to
slow release over a long period of time via desorption as the polymer degrades. Since this
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physicochemical interaction between LA and PLGA controls drug release18, any unintended
change to this interaction may result in undesirable changes in the drug release rate and duration.
For example, solvents (DCM/DMSO/MeOH) have the potential to alter the physicochemical
interaction between LA and PLGA during the manufacturing process. This in turn may alter
peptide distribution as well as peptide-polymer interaction, resulting in alteration of the release
characteristics.
FT-IR spectra of PLGA and LA in formulations F1 and F3 (prepared using different solvent
systems) were evaluated for any changes (shift in the wavenumber or intensity) in their
characteristic absorbance bands (Table 5) compared to pure LA, PLGA and their physical
mixture (Figure 5). As shown in Figure 5B, the intensity of the characteristic bands of LA in the
physical mixture and the prepared LA microspheres were reduced compared to the pure LA
spectra (Figure 5A). This is due to the lower amount of LA (8%) compared to PLGA (92%). No
other significant changes in the spectra of the microsphere formulations (Figure 5A) were
observed compared to the pure LA, PLGA and the physical mixture (Figure 5B) except for the
N-H stretching band. This indicates that there is no significant interaction between the drug and
the polymer except for weak hydrogen bonding (N-H stretching band – 3269, 3323 and 3333
cm−1 in the physical mixture and formulations F1 and F3, respectively). Moreover, the FT-IR
spectra of the formulations prepared with different solvent systems (Figure 5A) were also
similar except for the difference in the N-H stretching band. This indicates that there is no impact
of the solvent system on LA-PLGA interaction in the dry microspheres, implying that the
reported physicochemical interaction between LA and PLGA18 possibly occurs only in the
presence of aqueous media (water or release medium) at neutral or lower pH and not in the dry
state.

84

-1

Table 5. Characteristic FT-IR absorption bands (cm )
Characteristic absorption bands

Chemical structure

-1

(cm )
PLGA25,26

~2996, 2946 (CH, CH2. CH3
stretching), ~1745 (ester C=O
stretching), ~1381, 1423, 1451 (C=O
bending vibrations), -1268 (C-C(=O)-0
symmetric/asymmetric stretching),
1150-1350 (CH2, CH wagging),
~1082, 1128 (C-O ester stretching)

LA27

~3269 – broad band (O-H,
amide/amine N-H stretching), ~2996
(CH, CH2. CH3 stretching), ~1630
(amide C=O stretching), ~1535,1514
(N-H bending), ~1400-1600 (aromatic
C=C stretching), ~1350-1480 (-CH
(alkane) bending), ~1239 (C-N
stretching)

F3

PLGA

F1
Physical
Mixture
LA

Physical Mixture
(LA:PLGA(8:92 %W/W))

N-H peak shi – May be due to
weak hydrogen bonding
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Figure 5. (A) Overlay of FT-IR spectra of LA, PLGA and physical mixture (LA:PLGA, 8:92%
w/w) and (B) Overlay of FT-IR spectra of prepared LA microsphere formulations
F1_DCM/MeOH and F3_DCM/DMSO and physical mixture (LA:PLGA, 8:92% w/w)
In vitro degradation study:
Hydrolytic degradation of the PLGA in aqueous release media is one of the major
mechanisms for drug release from PLGA microspheres. It has been reported14,15,28-29 that
differences in the particle size and porosity of the prepared microspheres as a result of
manufacturing differences may lead to an altered surface area to volume ratio and extent of water
diffusion inside the particles and hence, differences in the polymer degradation rate. This may be
responsible for the observed differences in the microsphere drug release characteristics.
Therefore, an in vitro degradation study was conducted to evaluate any difference in the polymer
degradation kinetics of the microspheres during release testing. However, as shown in Figure 6,
no significant differences in the polymer degradation rate (as shown by decrease in molecular
weight) were observed among the microspheres formulations with different size and porosity.
This may be a result of the faster degradation rate of the low M.wt. PLGA of LA microspheres
compared to that of previously reported high molecular weight PLGA micropsheres30. Thus, the
differences in release characteristics of the various microsphere formulations are not due to the
changes in polymer degradation rate.
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Figure 6. Degradation kinetics of
PLGA microspheres prepared with
minor manufacturing differences under
in vitro release testing conditions (33
mM PBS containing 0.02% w/w
sodium azide and Tween 20, pH 7.4 at
37°C)
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The diffusion of the peptide from the polymer matrix into the release media is another major
release mechanism. Microsphere samples from the in vitro degradation study were evaluated for
impact of morphological differences (such as pore diameter, shape and network) on the
diffusion-based peptide release. As shown in Figure 7, as degradation proceeded, both
microsphere formulations appeared to follow the typical “inside-out” degradation mechanism. It
was evident that the more porous microspheres i.e. formulation F3 degraded faster with
formation of large pores and channels inside the microspheres by day 15 (as shown by the yellow
arrow) compared with the less porous microspheres (i.e. formulation F1). The formation of pores
and channels inside the F1 formulation became evident only after day 15. These differences in
microsphere structure may be responsible for the observed differences in the drug release rates
during the initial 15-day period (Figure 4B), especially since LA is large in size and hence, may
have pore size/structure restricted diffusion and release. After 15 days, polymer erosion
progressed extensively leading to complete shape deformation and exposure of greater surface
area. No significant difference in pore structure and hence, release rate was observed after day
20 (Figure 4B).
Similar morphological changes as formulations F1 and F3 were observed for formulations F2
and F4, prepared using the same solvent system despite their larger size (data not shown).
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Figure 7. SEM images of LA microsphere formulations F1_DCM/MeOH and
F3_DCM/DMSO under in vitro release testing condition (33 mM PBS containing 0.02%
w/w sodium azide and Tween 20, pH 7.4 at 37°C) over a period of 50 days. Symbols: the
red arrows point to pores on the surface of the microspheres; the blue arrows point to
differences in the indentations on the surface of the microspheres; the yellow arrows point
to the differences in pore structure.
4.3.3. In vivo release characteristics of the LA microspheres
The pharmacokinetic profiles of the LA microspheres following intramuscular (i.m.)
administration in rabbits are shown in Figure 8. All the prepared compositionally equivalent LA
microsphere formulations and the RLD product exhibited bi-phasic in vivo release profiles with
variable burst release phase followed by slow and continuous zero–order release over 40 days.
The key pharmacokinetic parameters of each microsphere formulation were determined and are
listed in Table 6. Similar Tmax of 3.5 h with variable Cmax concentrations corresponding to the
burst release were observed for all formulations and the RLD product (Table 6). Formulation F2
had the lowest Cmax while formulation F3 had the highest Cmax with F1 and F4 having
intermediate Cmax. Moreover, formulation F2 had the lowest AUC0-last while F3 had the highest
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AUC0-last with F1 and F4 having intermediate AUC0-last values. F2 had the longest T1/2 compared
to all other formulations.
Plasma concetration vs time profile (Rabbits, n=6)
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Table 6. Pharmacokinetic parameters of leuprolide acetate microspheres (i.m., rabbits)
Formulation
(n=6)

Tmax
(day)

Cmax
(ng/ml)

AUC0last

T1/2
(day)

F1

0.15

4.22

66.97

17.73

F2

0.15

2.87

54.89

23.83

F3

0.15

7.43

76.30

15.59

F4

0.15

5.80

74.69

12.42

Lupron
Depot®

0.15

9.49

69.03

24.15

The differences in the in vivo burst release and release rate are similar to the in vitro release
profiles of the various formulations and result from differences in their physicochemical
properties.
4.3.4. Pharmacokinetic Analysis and development of IVIVC
4.3.4.1. Pharmacokinetic analysis of LA in rabbits:
The PK study of the LA solution following single intravenous (i.v.) administration was used
to determine its PK parameters (Table 7) i.e. the distributive and elimination micro rate
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constants (k12, k21 and k10), which are necessary for deconvolution of the LA microsphere in vivo
release profiles into the total fraction absorbed using the Loo-Riegelman method19.
Table 7. Pharmacokinetic parameters of the LA solution (i.v.) (Software: WinNonlin® 6.4).
-1

-1

-1

-1

A

B

α (h )

β (h )

K10 (h )

K12(h )

K21(h-1)

46.34

6.40

4.90

0.39

2.04

2.31

0.93

4.3.4.2. Deconvolution of the in vivo release profiles of LA microspheres
The in vivo plasma concentration vs time (PK) profiles (i.m.) of the LA microspheres were
deconvoluted into the fraction absorbed vs time using the pharmacokinetic parameters (Table 7)
of LA in rabbits and the Loo-Riegelman deconvolution method19. The deconvolved fraction
absorbed vs time profiles of the prepared LA microspheres and the RLD product are shown in
Figure 9. Overall, the deconvolved in vivo LA release from PLGA microspheres appeared to be
faster compared to their respective in vitro release profiles. This may be due to accelerated
polymer degradation as a result of local acidic pH and/or the presence of other biological
components (such as enzymes) in the interstitial tissue fluid at the intramuscular injection site.
Despite the difference in the in vivo and in vitro release rates, the in vivo release profiles of all
formulations followed a similar rank order as the in vitro release profiles: RLD>formulation F3
> formulation F4 > formulation F1> formulation F2. This indicates that the release mechanisms
under in vitro and in vivo conditions appear to be similar, which is one of the major requirements
for the development of IVIVCs1. Interestingly, it was observed that the in vivo burst release was
significantly lower than each respective in vitro burst release. This may be due to the masking
effect of poor or slow absorption of the peptide into the systemic circulation as a result of
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hydrophilicity, larger size, steric hindrance and/or charge interaction with the extracellular
matrix at the intramuscular site.
Overall, comparison of the deconvoluted in vivo release profiles with the respective in vitro
release profiles of the LA microspheres suggested the feasibility of developing a point-to-point
IVIVC model, but with the use of mathematical parameters to account for the difference in the
release rate and % burst release under in vitro and in vivo conditions.
Figure 9. Deconvolved in vivo profiles
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4.3.4.3. In vitro - in vivo correlation of the LA microspheres
The U.S. FDA guideline1 recommends the use of a minimum of two, preferably three or more
formulations with different release rates to define an IVIVC. Therefore, all four prepared LA
microsphere formulations with different in vitro and in vivo release rates were used in developing
IVIVC(s) in different combinations of three out of four formulations. Based on the knowledge
obtained from our previous research on risperidone14 and naltrexone15 microspheres,
formulations on the extremes of the release profile range (i.e. formulations F2 and F3) were
included in the different combinations of formulations studied to develop correlation models
with better predictability and wider application scope. Accordingly, a total of two different
combinations of three formulations (i.e. F1, F2, F3 and F2, F3, F4) were investigated. First of all,
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the in vitro release profiles were simulated via model fitting using Origin Pro (data analysis
software) to synchronize the sampling time interval with the in vivo release profiles. Due to the
differences in the release rate and release duration of the in vitro and deconvoluted in vivo
release profiles, time scaling (1/1.65) and time shifting (+1) factors (determined using a Levy
plot - in vivo vs in vitro time for definite fraction released) were used to achieve a 1:1 correlation.
As recommended by the FDA guidance, the same time-scaling/shifting factors were applied to
all formulations used for the development and validation of the IVIVCs. The fraction
absorbed/released in vivo of selected formulations was plotted against the fraction released in
vitro at the respective time point to establish a correlation if any. As shown in Figure 10 (A and
D), an affirmative point-to-point correlation i.e. a Level A IVIVC1 between the fractions released
in vitro and fractions released/absorbed in vivo was observed for all combinations using a simple
linear regression model (correlation coefficients greater than 0.97). All the developed IVIVCs
were comparable as manifested by similar slopes and intercepts.
These developed IVIVCs were then used to predict the in vivo profiles of the fourth
remaining external formulation using the real time in vitro release profiles. As shown in Figure
10 (B and E), the predicted in vivo profiles of the external formulations overlapped with the
observed deconvoluted in vivo release profiles for both IVIVC models, indicating that the models
are predictable.
The developed IVIVCs were also used to predict the in vivo release/absorption profile of the
Lupron Depot®, RLD product from its “real-time” in vitro release profile. As shown in Figure
10 (C and F), the predicted in vivo release profiles were very similar to the observed
deconvoluted in vivo profiles obtained in rabbits irrespective of which IVIVC model was used.
These results showed that the developed IVIVCs were sufficiently robust. Most importantly, the
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developed IVIVCs can be used to predict not only the LA microsphere formulations that are
equivalent in formulation composition but also a microsphere formulation that is not equivalent
in composition but has similar drug loading.
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Figure 10. Level A IVIVC for LA microspheres using the two-stage deconvolution
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approach based on the Loo-Reigelman method. (A) IVIVC developed using
formulations F2, F3 and F4 (IVIVC 1). (B) Experimental and predicted in
vivo release profiles of formulation F1, based on IVIVC 1. (C) Experimental and
predicted in vivo release profiles of RLD product, Lupron Depot®, based on IVIVC
1. (D) IVIVC developed using formulations F1, F2 and F3. (E) Experimental and
predicted in vivo release profiles of formulation F4, based on IVIVC 2. (F)
Experimental and predicted in vivo release profiles of RLD product, Lupron Depot®,
based on IVIVC 2
All the developed IVIVCs were internally as well as externally validated for their
predictability as per the FDA guidance1. The predictability of the IVIVCs was estimated in terms
of % prediction error (PE) of Cmax and AUC0-last using WinNonlin® 6.4 software. As shown in
Table 8, the average absolute internal % PE for the Cmax (9.52%) of IVIVC 2 was within the
recommended range of 10% or less. However, the average absolute internal % PE for AUC0-last
(10.94%) was slightly more than 10%, suggesting the internal predictability of the developed
IVIVC 2 for the AUC0-last was inconclusive. Accordingly, evaluation of external predictability of
the IVIVC 2 was performed. As can be seen in Table 8 the external % PE for the Cmax and
AUC0-last were 1.52% and 2.83%, respectively, which passes the recommended external
predictability evaluation (% PE of 10% or less). These results indicate that the developed IVIVC
2 has good external predictability, and thus could be used as a surrogate for bioequivalence
studies in rabbits.
Furthermore, the predictability of the developed IVIVC 2 for the RLD was also investigated.
Both % PEs for Cmax (8.40%) and AUC0-last (-8.31%) were below 10%. These results confirmed
that the developed IVIVC 2 has potential to be used to predict the in vivo performance of not
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only the compositionally equivalent LA microsphere formulations with manufacturing
differences but also LA microsphere formulations that are not compositionally equivalent.
Moreover, the successful development of the validated IVIVC 2 model also indicates that the
developed sample-and-separate in vitro release testing method had good predictability of the in
vivo performance of leuprolide acetate polymeric microspheres.
Table 8. Validation and prediction of the developed IVIVC_2 for LA microspheres.
AUC0-last (μg/l * day)

Cmax (μg/l)
Internal
Obs.

Pred.

%PE

Obs.

Pred.

%PE

Formulation F1

4.22

3.96

-6.18

66.97

61.42

-8.28

Formulation F2

2.87

2.38

-16.95

54.89

62.68

14.20

Formulation F3

7.43

7.02

-5.43

76.30

68.41

-10.34

Average

4.84

4.45

9.52

66.05

64.17

10.94

5.80

5.71

-1.52

74.69

72.58

-2.83

9.49

10.29

8.40

69.03

63.29

-8.31

validation

Internal
External Validation
Formulation F4
RLD Prediction
Lupron Depot®

Please note that external % PE for the IVIVC_1 was within the acceptance criteria in terms
of Cmax (-8.92%) but slightly higher for the AUC0-last (-10.85%). Accordingly, it was not
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considered a validated IVIVC model although it did not show significant difference in the
predictability of in vivo profile (Figure 10 B and C).
4.4. Conclusions:
The present manuscript describes for the first time that Level A IVIVCs can be developed
for compositionally equivalent PLGA microspheres containing large molecular weight and
complex molecules such as peptides. It was observed for the first time that slow absorption of
peptide at the intramuscular site masked the high burst release that was observed under in vitro
release testing conditions. This difference in the burst release phase under in vitro and in vivo
conditions complicated the development of an IVIVC. Accordingly, multiple mathematical
parameters were needed to achieve a 1:1 linear Level A correlation. Together with our previous
research on developing Level A IVIVCs for polymeric microspheres containing small molecules,
it can be concluded that Level A IVIVCs can be developed for a variety of complex parenteral
microsphere drug products using in vitro release testing methods and a rabbit model. This shows
the potential of developing IVIVCs using clinical data for such complex parenteral drug
products, which can serve as surrogates for bioequivalence studies.
The critical quality attributes and performance of microspheres containing large
molecular weight and complex molecules such as peptides were shown to be sensitive to minor
manufacturing changes. This is particularly significant for microspheres containing substantial
amount of potent drugs such as peptide. It was also shown that the hydrolytic degradation of low
molecular weight PLGA was not sensitive to differences in particle size and porosity. However,
the drug release characteristics of such microspheres containing relatively large hydrophilic
molecules such as peptide were sensitive to changes in the microsphere pore structure.
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Chapter 5

In vitro-in vivo correlation of parenteral polymeric microspheres: Effect of variable burst release
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Abstract:
Development of IVIVCs is a very complicated process, especially for complex drug products such as
parenteral PLGA microspheres with multiphasic drug release characteristics. Specifically, microspheres
that exhibit an initial burst release phase are even more challenging since the in vitro and in vivo burst
release phases may not be comparable if drug absorption is rate-limiting at this stage. Therefore, the
objectives of the present work were: 1) to investigate the predictability of IVIVCs for the in vivo burst
release phase based on the in vitro burst release phase of the formulations; and 2) to evaluate the impact
of variable burst release on the predictability of the developed IVIVCs for two different types of
microsphere drug products. Accordingly, Risperdal Consta® (Risperidone) and Lupron Depot®
(Leuprolide acetate, LA) were selected as model microsphere products. Q1/Q2 equivalent risperidone and
LA microsphere formulations with variable burst release phases were prepared with manufacturing
process changes (such as solvent systems and mixing methods). The prepared microspheres had
differences in critical physicochemical properties (such as particle size, porosity, average pore diameter,
and drug distribution) and hence differences in their in vitro release characteristics (such as variable burst
release and release rate). The in vitro and in vivo (rabbit model (i.m.)) burst release were similar for the
risperidone microspheres but were significantly different for the LA microspheres. This had an impact on
the complexity of the developed IVIVC models. Level A IVIVCs with the ability to predict various types
of burst release were developed using time scaling and shifting factors. Moreover, it was observed that
IVIVCs developed using formulations with less variation in burst release had better predictability and
vice-versa. Thus, the present research has provided an in-depth understanding of the impact of the burst
release phase on the development, complexity, and predictability of IVIVCs for complex parenteral
microspheres containing a variety of therapeutic molecules.
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5.1. Introduction:
As per the U.S. FDA guiedance1, an in vitro – in vivo correlation (IVIVC) is a predictive
mathematical model describing the relationship between an in vitro property of a dosage form and a
relevant in vivo response. It is an important biopharmaceutical tool used in formulation development to:
speed up the initial screening process; widen dissolution specifications; and most importantly serve as a
surrogate for in vivo BE studies during initial prodcut development as well as certain scale-up and
postapproval changes (SUPAC). However, the development of a predictive and robust IVIVC model is a
very complex process. To develop an effective IVIVC, the physicochemical and biopharmaceutical
properties of the drug2 (such as drug solubility, pKa, drug permeability) and dosage form (size, polymer
type, release characteristics, stability etc.) as well as the physiological environment (pH, fluid volume,
tissue response, site of absorption etc.) in the body must be taken into consideration. A detailed regulatory
guidance on various aspects of IVIVC development for extended release oral products is available 1. In
addition, the development of IVIVCs for oral products has been widely investigated and reported in the
literature, highlighting various critical factors (such as mean vs individual profile, time scaling and
shifting) that may need to be considered3.
However, long acting parenteral drug products (such as PLGA microspheres) are more complex and
significantly different compared to extended release oral products in terms of their release characteristics
as well as physiological conditions at the site of administration4,5. For example, PLGA microspheres have
complicated multiphasic release profiles (i.e. burst release phase, lag phase and secondary release phase)
with different release rates for each phase6-10. Additionally, there are very few reports on the development
of IVIVCs for such products4. Accordingly, it is essential to investigate specific and critical attributes that
need to be considered during development of IVIVCs for such complex parenteral drug products. It has
been reported that the in vivo absorption phase at the intramuscular site can mask high burst release
observed under in vitro conditions11. In addition, fibrous encapsulation of microspheres through the host
immune response9,10,12-14 or steric hindrance by the extracellular matrix may lower the in vivo burst
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release. These factors make it difficult to develop IVIVCs with an ability to predict initial in vivo drug
release. It was observed during our previous work that IVIVCs developed using formulations with
significant variations in the burst release phase had limited ability to predict the burst release phase 15-16.
Accordingly, it is essential to investigate formulations with and without a burst release phase, as it may be
important to distinguish between these different types of formulations when considering the development
of IVIVCs for microspheres.
Building on the knowledge and experience gained through our previous work as well as literature
reports, the objectives of the present work were to investigate the ability of IVIVCs to predict the in vivo
burst release based on the in vitro burst release of formulations, and to evaluate whether IVIVCs
developed based on high burst release microsphere formulation(s) are able to predict the in vivo
performance of microsphere formulation(s) with no or minimal burst release and vice versa. Two PLGA
microspheres drug products with different physicochemical properties and drug release characteristics i.e.
Risperdal Consta® (risperidone) and Lupron Depot® (leuprolide acetate) were investigated to provide a
comprehensive understanding of the impact of burst release on the development and predictability of
IVIVCs for complex parenteral microspheres. Compositionally equivalent risperidone and leuprolide
acetate microsphere formulations with high as well as low in vitro burst release were prepared through
manufacturing process changes and characterized for various physicochemical properties and release
characteristics under in vitro and in vivo conditions. Level A IVIVCs with the ability to predict the
complete release profiles including variable burst release phase, were developed and validated in terms of
internal as well as external % prediction error for Cmax and AUC

0-last

for the microspheres products

investigated.
5.2. Material and methods:
5.2.1. Materials
PLGA (Resomer® 7525 DLG 6E and Resomer® Select 7525 DLG 2CA) were purchased from Evonik
(Birmingham, AL). Risperidone was purchased from Jai Radhe, India. Leuprolide acetate (LA) and
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reference standard (i.e. LHRH acetate salt) were purchased from Bachem Americas, Inc (Torrance, CA).
Poly(vinyl alcohol) (PVA, M. Wt. 30–70 kDa), trifluoroacetic acid (TFA), and reference standards (i.e.
risperidone, and risperidone-D4) were purchased from Sigma-Aldrich (St. Louis, MO). Methylene
chloride, methanol, acetonitrile (ACN, HPLC grade) and dimethyl sulfoxide (DMSO, ACS grade) were
purchased from Fisher Scientific (Pittsburgh, PA). ). LC-MS grade 0.1% v/v formic acid in water, 0.1%
v/v ammonium acetate in water, acetonitrile and methanol were purchased from VWR (Radnor, PA).
Milli-Q® water was used for all studies. All other chemicals were obtained commercially as analyticalgrade reagents.
5.2.2. Preparation of microspheres
5.2.2.1. Risperidone microspheres
PLGA with a similar molecular weight as that used in the commercial product Risperdal Consta ® was
used to formulate compositionally equivalent risperidone microspheres with manufacturing differences
(e.g. homogenization, vortex mixing, and different solvents). Briefly, when methylene chloride (DCM)
was used as the solvent, both PLGA and risperidone (polymer/drug, 4/3 (w/w)) were dissolved in DCM
and mixed with other cosovlents (Table 3). The polymer/drug solution was then dispersed into an
aqueous PVA solution (1%, w/v) saturated with DCM to form an oil-in-water (o/w) emulsion via
homogenization (3400 rpm, 2 min) (IKA® Works, Inc.). The microparticles were hardened via
evaporation at room temperature for 3 h and then the solvent was further removed under vacuum. The
resulting microspheres were collected, washed using distilled water and lyophilized. Different sieving
procedures using 25 μm and 212 μm sieves for wet sieving (pre-lyophilization) and only 212 μm sieve for
dry sieving (post-lyophilization) were used. When ethyl acetate (EA) and benzyl alcohol (BA) were used
as the solvent system, PLGA was dissolved in EA (16.7%, w/w) and risperidone was dissolved in BA
(24%, w/w), respectively. The polymer and the drug solutions were then mixed and transferred to the 1%
(w/v) PVA solution (saturated with EA) to form oil-in-water (o/w) emulsion via homogenization (3400
rpm, 30 s) or vortex mixing (1200 rpm, 10 s). The resulting emulsions were transferred to a solvent
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extraction medium (2.5% (v/v) EA in water) and the solvent was extracted overnight at 4 °C. Following
solvent extraction, residual organic solvents were removed under vacuum at room temperature, following
which the microspheres were collected and washed using an aqueous alcoholic solution (25% ethanol,
v/v). The resulting microspheres were wet sieved using 25 μm and 212 μm sieves and lyophilized.
5.2.2.2. Leuprolide acetate microspheres
PLGA (M.wt. ~15KDa) with a similar molecular weight as that used in the commercial product
Lupron Depot® was used to formulate compositionally equivalent LA microspheres using different
manufacturing processes. Briefly, 200 mg of PLGA were dissolved in methylene chloride (45%, w/v). LA
is poorly soluble in methylene chloride and accordingly, a co-solvent (such as methanol, benzyl alcohol,
and DMSO (Table 4)) was used to facilitate dissolution of LA. The LA solution was added to the
polymer solution to form the organic phase and mixed by vortexing. The organic phase containing both
the polymer and drug was then dispersed into a 0.35% (w/v) PVA solution to form an oil-in-water (o/w)
emulsion using a homogenizer ((IKA® Works, Inc.) set at 14,000 rpm for 10 seconds followed by 13,000
rpm for 90 seconds. Leuprolide acetate microspheres with large particle size were prepared using a lower
emulsification/size reduction force (homogenization at 9000 rpm for 10 seconds followed by 8000 rpm
for 90 seconds). The resultant o/w emulsion was stirred at 400 rpm for 3 h under vacuum at room
temperature to allow microsphere solidification and solvent evaporation. The resultant microspheres were
collected, washed using distilled water, and lyophilized. The resulting dry microspheres were sieved
using 75 μm sieve.
5.2.3. Characterization of microspheres
5.2.3.1. High performance liquid chromatography (HPLC) analysis
5.2.3.1.1. Risperidone microspheres:
The quantification of risperidone was conducted using a Perkin Elmer HPLC system (series 200) with
a UV absorbance detector set at 275 nm. A mobile phase consisting of acetonitrile/water/TFA (30/70/0.1,
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v/v/v) at a flow rate of 1 mL/min and a Kinetex C18 column (250 × 4.6 mm, 5 μm, 100 Å) column were
used. The sample injection volume was 10 µL for drug loading and 50 µL for in vitro release testing
sample analysis. The chromatographs were analyzed using a PeakSimple™ Chromatography System (SRI
instruments, Torrance, CA).
5.2.3.1.2. Leuprolide Acetate microspheres:
The quantification of LA was conducted using an Agilent HPLC system (series 1200) with a UV
absorbance detector set at 220 nm (release test samples)/280 nm (drug loading test samples). A mobile
phase consisting of 0.1% (v/v) trifluoroacetic acid in water (A) and Acetonitrile (B) was used for
separation of LA through gradient elution (Table 1) at 30°C. A Kinetex® EVO C18 column (250 x 4.6
mm, 5μm, 100Å, Phenomenex) was used as the stationary phase. The sample injection volume was 20 µL
for drug loading and 50 µL for in vitro release test sample analysis. The chromatographs were analyzed
using a Agilent OpenLAB chromatography data system.
Table 1. HPLC gradient elution method for leuprolide acetate analysis

Flow rate
Time (min)

%A

%B

(mL/min)
0

1.0

90

10

10

1.0

80

20

12

1.0

90

10

15

1.0

90

10

5.2.3.2. Drug loading
Five milligrams of the both the microspheres were weighed and transferred into 10 mL volumetric
flasks. DMSO (2.5 mL for risperidone and 2 mL for LA) was added into the volumetric flasks and the
samples were sonicated until all particles were dissolved. Methanol was added upto the 10 mL mark to
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dilute the sample. The solution was filtered (Millex® HV, 0.22 μm PVDF syringe filter) and the drug
concentration was determined with a validated HPLC assay method as described above. All the
measurements were conducted in triplicate and the results are reported as the mean ± SD. Drug loading
was calculated as:

Drug Loading (%)=

weight of drug entrapped
× 100
weight of microspheres analyzed

5.2.3.3. Particle size and particle size distribution
Particle size and particle size distribution of both the microspheres were measured using an
AccuSizer autodiluter particle sizing system (Nicomp, Santa Barbara, CA). Briefly, microspheres were
dispersed in 0.1% (w/v) PVA solution in water to ensure good dispersion, and then particle size analysis
was conducted. All the measurements were conducted in triplicate and the results are reported as the
5.mean ± SD.
5.2.3.4. Differential scanning calorimeter (DSC) analysis
The glass transition temperatures (Tg) of both the microspheres were analyzed using a modulated
temperature differential scanning calorimeter (MTDSC) (TA Instruments Q2000). Briefly, weighed
quantity (~ 5-6 mg) of each sample was transferred to standard aluminum pans and sealed with aluminum
lids. The DSC experiment was performed using a 2°C/min heating rate and a modulation amplitude of
± 0.82°C with an 80 s modulation period. All samples were subjected to a heat/cool/heat cycle. The
results were analyzed using TA analysis software, and the Tg was determined as the glass transition
midpoint in the reversing signal. The crystallinity of risperidone was also investigated.
5.2.3.5. Morphology
The morphology of the commercial product and the prepared microspheres was characterized using
scanning electron microscopy (SEM). Briefly, dry microspheres were mounted on carbon taped
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aluminum stubs and sputter coated with gold. The samples were analyzed using SEM (NanoSEM 450,
Nova).
5.2.3.6. Porosity
The porosity of the microspheres was determined using a Mercury Porosimeter (AutoPore IV 9500,
Micromeritics). Briefly, approximately 200 mg samples of the microspheres were introduced into the
porosimeter and tested at a mercury filling pressure of 0.53 psi. Total % porosity and average pore
diameter were recorded.
Porosity (%)=(1-

Bulk density
)× 100
Apparent (skeletal)density

5.2.3.7. Molecular Weight (M. Wt.)
The molecular weight of both the microspheres was determined by gel permeation chromatography
(GPC; Waters) with an evaporative light scattering detector (ELSD). The mobile phase was
tetrahydrofuran (THF) with a flow rate of 2 mL/min at 40◦C. Sample solutions in tetrahydrofuran (THF)
at a concentration of 1 mg/mL were filtered through a 0.45 μm filter (Millipore, USA) before injection
into the GPC system. The data collection and analysis were performed using Waters Millenium software.
Polystyrene standards (2000, 900, 824, 400, 200, 110, 43, 18.80, 17.60, 6.93, 2.61, 0.98 kDa) were used
for calibration and weight average molecular weights (M. Wt.) were calculated. All measurements were
conducted in triplicate and the results are reported as the mean ± SD.
5.2.4. In vitro release studies
5.2.4.1. Risperidone microspheres
In vitro release testing of the risperidone microspheres was investigated using the previously
developed USP apparatus 4 method [15]. Briefly, the microspheres (10 mg) were mixed with glass beads (1
mm) and placed in the USP apparatus 4 dissolution cells. PBS (10 mM, pH 7.4, 250 mL) with 0.01%
(w/v) sodium azide was circulated through the flow through cells at a flow rate of 8 mL/min at 37 °C. At
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pre-determined time intervals, 1 mL samples were withdrawn and replenished with fresh media. The
release samples were analyzed via HPLC.
2.4.2. Leuprolide Acetate microspheres
In vitro release testing of the LA microspheres was conducted using a previously developed sampleand-separate method at 37°C

(11)

. Briefly, 6 mg of microspheres were dispersed in 1 mL of phosphate

buffered saline (PBS containing 0.02% (v/v) Tween 20 and 0.02% (w/v) sodium azide, 33mM, pH 7.4) in
low protein binding eppendorf tubes mounted on a rotator set at 100 rpm and incubated at 37 °C. At predetermined time intervals, the release media were collected and centrifuged at 3,000 rpm for 3 min.
Supernatants (0.3 mL) were filtered through 0.22 μm filters and analyzed via HPLC. The release medium
was replaced with fresh media at each sampling time point.
Media replacement during release testing was taken into account in the calculation of the %
cumulative release. All drug release tests were conducted in triplicate and the results are reported as the
mean % cumulative release ± SD.
5.2.5. In vivo release studies of microspheres
In vivo release characteristics of both the risperidone and LA microspheres were investigated using a
rabbit model. Briefly, rabbits were randomLy assigned to cages and treated with the prepared microsphere
formulations and the commercial product (n = 6). The microspheres were suspended in the diluent used
for dispersion of commercial products prior to injection. The suspended microspheres were injected into
the rabbit hind leg thigh muscle (dose: 1.92 mg/kg for risperidone and 2.14 mg/kg for LA) and blood
samples were collected from the marginal ear veins at predetermined time intervals. The collected blood
samples were centrifuged for 5 min at 14,500 rpm and plasma was collected and stored at −20°C until
analysis. Risperidone and LA were extracted from the plasma samples and analyzed via LC-MS/MS. The
animal study protocol was reviewed and approved by the University of Connecticut's Institutional Animal
Care and Use Committee (IACUC) prior to beginning the experiments.
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5.2.6. Plasma sample analysis
5.2.6.1. Risperidone
Risperidone was extracted from plasma using tert-butyl methyl ether15. Risperidone-D4 was used as
an internal standard (IS). Briefly, the internal standard solution (100 ng/mL, 20 μl) was added into 200 μl
of plasma samples. Then tert-butyl methyl ether (1.1 mL) was added into the plasma samples and vortexmixed for 10 min followed by centrifugation at 14,000 g (4 °C) for 5 min. The supernatants were
transferred to the polypropylene centrifuge tubes and dried under nitrogen at 40 °C. The dry residues were
reconstituted in 100 μl of mobile phase (0.1% formic acid in water/methanol: 80/20 (v/v)) and analyzed
using a previously developed LC–MS/MS analytical method15.
Chromatographic separations were carried out on a Kinetex Biphenyl column (50 × 2.1 mm, 2.6 μm,
100 Å) through gradient elution of mobile phase at 0.3 mL/min and 40 °C. Mobile phase A was 0.1%
formic acid in water (LC–MS); mobile phase B was methanol (LC–MS). The gradient started at 80%
mobile phase A and was decreased to 5% over 8 min, then held constant for an additional 1 min. At 10
min, the column was returned to 80% mobile phase A and re-equilibrated for 8 min. The MS detection
parameters were: 3500 V electrospray voltage, 300 °C capillary temperature, and 30 V collision energy.
Detection of ions was conducted in the positive-ion selected reaction monitoring mode with the following
transitions: m/z 411.1 → 195.1 for risperidone, and m/z 415.1 → 195.1 for risperidone D4. The injection
volume was 10 μl. The data acquisition was ascertained by Xcalibur software. The lowest limit of
quantification (LLOQ) for risperidone was 0.517 ng/mL and the mean recovery of plasma samples from
low to high concentrations of risperidone was more than 90%.
5.2.6.2. Leuprolide Acetate
LA ((Des-Gly10, D-Leu6, Pro-NHEt9)-LHRH), M.wt. 1209.42 Da) was extracted from plasma samples
using a protein precipitation extraction method11. LHRH ((Des-Gly10, D-Ala6, Pro-NHEt9)-LHRH, M.wt.
1167.34 Da) acetate salt was used as the internal standard (IS). Briefly, 100 μl plasma samples were
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mixed with 100 μl drug solution in diluent (0.1% formic acid in water: acetonitrile (90:10, %v/v) for the
preparation of calibration standards (1, 2.5 5, 10, 15, 20 and 30 ng/mL) or 100 μl of diluent for study
samples. All samples were then spiked with 20 μl of the IS solution (200 ng/mL in methanol). Ice-cold
acetonitrile was then added in a stepwise fashion (two-steps, each of 500 μl) to the pre-treated plasma
samples and vortex-mixed for 10 minutes at 2,500 rpm followed by centrifugation at 14,500 rpm (4°C)
for 8 minutes. The supernatants were transferred to the low-protein binding polypropylene (PP) centrifuge
tubes and dried under nitrogen at 40°C. The dry residues were then reconstituted in 100 μl of diluent
(0.1% formic acid in water/acetonitrile, 90:10 %v/v). 25 μl of the reconstituted solution was used for LCMS/MS analysis.
Chromatographic separations were carried out on a Kinetex EVO C18 column (50 x 2.1 mm, 2.6 μm,
100 Å) through gradient elution (Table 2) at 35°C. The following MS detection parameters were used:
4400 V electrospray voltage, 320°C capillary temperature, and 35 V collision energy. Detection of ions
was conducted in the positive-ion selected reaction monitoring mode with the following transitions in a
single reaction monitoring (SRM) mode: m/z 605.5 to 249.1 for leuprolide acetate, and 584.67 to 249.1
for the IS. The injection volume was 25 μl. The data acquisition was ascertained by Xcalibur software.
Calibration curves were established on each day when analysis was conducted and showed good linearity
with correlation coefficients > 0.99. The lowest limit of quantification (LLOQ) for LA was 1 ng/mL and
the mean recovery of plasma samples from low to high concentrations of LA was more than 90%.
Table 2. HPLC gradient method for the determination of leuprolide acetate content in rabbit plasma.

Time

Flow rate

0.1% formic Acid/0.1% ammonium

(min)

(mL/min)

acetate (21/, v/v), %

0

0.3

95

5

5

0.3

40

60

8

0.3

40

60

ACN, %
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9

0.3

95

5

12

0.3

95

5

5.2.7. Development of IVIVCs
The relationship between fraction of drug released in vitro and the fration of drug absorbed in vivo from
the prepared micropshere formulations was assessed using a two stage based deconvolution approach
following the same principles as detailed in the U.S. FDA IVIVC guidance on extended release oral
dosage forms1. Briefly, the in vivo plasma profiles of the prepared risperidone and LA PLGA
microspheres were deconvoluted using the Loo–Riegelman method

[16]

. Standard errors are not shown in

the deconvoluted in vivo profiles because the average plasma concentration values were used. The
fraction absorbed in vivo was calculated as below:
t
Ab Cp +Ct +K10 (AUC)0
=
Ab∞
K10 (AUC)∞
0

Cp, Ct, K10 and AUC are the drug concentration in the central compartment (plasma), apparent tissue
compartment concentration, elimination rate constant and area under the plasma vs. time curve,
respectively. The previously determined distributive and elimination micro rate constants (k12, k21 and
k10) 10,15 were used for calculating Ct.
2.8. Statistical analysis
Statistical data analysis was performed using a paired student t-test. The level of significance was
accepted at p < 0.05.
5.3. Results and Discussion:
5.3.1. Physicochemical properties of the risperidone microspheres:
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Compositionally equivalent risperidone microspheres with variable burst release were prepared using
a single emulsion solvent evaporation method with minor manufacturing differences (Table 3). As shown
in Table 3, all the formulations prepared using different manufacturing processes were optimized to have
similar drug loading (~37 % w/w), which indicates that all the prepared formulations were
compositionally equivalent.
Table 3. Q1/Q2 equivalent risperidone microsphere prepared with manufacturing differences
Formulation

Solvent

Preparation Method

System/ratio
Risperdal

-

% DL

% Porosity

(Mean ± SD)
-

39.42±1.92

43.97 ± 4.60

36.77±1.44

46.04

37.67±0.94

43.19

38.20±0.89

61.01

Vortex & wet sieving

37.33±0.60

54.98

EA/BA

Homogenization & wet

36.45±1.23

61.75

(1/0.42 w/w)

sieving

DCM/BA

Homogenization & wet

36.69±2.89

48.43

(1/0.2 w/w)

sieving

DCM/Methanol

Homogenization & wet

37.68±0.52

47.18

(1/0.2 w/w)

sieving

Consta®
High burst release formulations
Formulation 1

Formulation 2

Formulation 3

DCM

Homogenization & dry

(1.2 g)

sieving

DCM

Homogenization & wet

(1.2 g)

sieving

DCM/EA

Homogenization & wet

(0.7/0.5 w/w)

sieving
Low burst release formulations

Formulation F4

EA/BA
(1/0.42 w/w)

Formulation F5

Formulation F6

Formulation F7
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DCM - Dichloromethane; EA - Ethyl Acetate; BA - Benzyl Alcohol

As shown in Figure 1A, in terms of population distribution, formulation F1 had significantly lower
size compared to the RLD product and formulations F2 and F3. This is probably a result of formulation
F1 being prepared using a dry sieving procedure, which retains smaller particles (<25 um) that otherwise
would be removed during the wet sieving procedure used for the other formulations. In terms of volume
distribution, no significant differences in particle size and size distribution were observed among the
prepared formulations with high burst release phase and the RLD product.
As shown in Figure 1B, formulation F4 had particle size and size distribution similar to the RLD
product, Risperdal Consta®, but significantly different than the other prepared formulations, F5, F6 and
F7. Compared to formulation F4, formulation F5 had lower particle size as it was prepared using a
stronger homogenization force. Similarly, formulations F6 and F7 prepared using homogenization had
lower particle size compared to F4 but only in terms of volume distribution. In terms of population
distribution, formulations F6 and F7 had similar or higher particle size compared to F4. This may be due
to the use of a lower solvent amount in the preparation of formulations F6 and F7 leading to increased
polymer solution concentration and viscosity, which ultimately resulted in the formation of larger
particles, of the same size as formulation F415. In addition, methanol has high viscosity compared to the
other solvents used, which may lead to further increase in polymer solution viscosity and hence, particle
size.
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Polymer solution
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Figure. 1. Particle size and particle size distribution of Risperdal Consta®
and the prepared risperidone microspheres A) High burst release
formulations; B) Low burst release formulations. All values are expressed
as mean ± SD (n = 3 batches); C) Factors affecting particle size of
microspheres.
As shown in Figure 2, risperidone formulations prepared using DCM based solvent systems (F1, F2,
F6 and F7) were polydisperse and of spherical shape with smooth surfaces. On the other hand, the
risperidone formualtions prepared using the EA/BA solvent system (i.e. formulations F3, F4 and F5)
showed some irregular shapes and indentations, a morphology similar to that of Risperdal Consta®.
These differences in morphology were further evaluated by determination of the porosity of these
formulations. As shown in Table 3, the risperidone microspheres prepared using DCM as the solvent (i.e.
Formulations F1, F2, F6 and F7) showed the lowest % porosity, indicating that these microspheres have a
denser structure as indicated by the morphology. While formulation F3, F4 and F5 prepared with EA
showed higher % porosity compared to the other formulations. This may be due to rapid evaporation of
the lower boiling point DCM at room temperature compared to gradual solvent extraction of the higher
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boiling point EA and BA at 4°C during the microsphere solidification process. This, in turn, results in
rapid polymer precipitation and hence, dense particles in the DCM based formulations compared to the
EA/BA based formulations. Slower solvent removal via extraction for EA/BA based formulations leads
to dynamic solvent exchange during solidification resulting in water inclusion inside the microspheres,
which generates pores upon solvent removal during lyophilization

11

. No significant differences were

observed in other physicochemical properties such as polymer molecular weight (~75 KDa) and Tg
(~42°C) of all the prepared formulations.
Risperdal Consta®

F6

F1 and F2

40 µm

200 µm

20 µm

100 µm

20 µm

300 µm

A

F4 and F5

B

100 µm

100 µm

F7

F3

5 µm

300 µm

30 µm

50 µm

Figure 2: SEM images
of
morphology
of
Risperdal Consta® and
the prepared risperidone
microsphere
formulations: A) High
burst
release
formulations; and B)
Low
burst
release
formulations.

5.3.2. Physicochemical properties of the leuprolide acetate (LA) microspheres:
As shown in Table 4, despite the differences in the solvent systems used, all the prepared LA
microsphere formulations had similar drug loading, which indicates that the prepared microsphere
formulations are compositionally equivalent.
Table 4. Q1/Q2 equivalent LA microsphere formulations prepared with manufacturing differences

Solvent

Drug

system (Ratio,

Loading

w/w)

(%, w/w)

-

6.88±0.77

Preparation
Formulation
Method

Lupron

-
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Average Pore
Porosity
(%)

-

Diameter
(nm)
-

Depot®
Homogenization

DCM/MeOH

F1
– High speed

(2.6/1)

Homogenization-

DCM/MeOH

Low speed

(2.6/1)

Homogenization

DCM/BA

F2

F3
– High speed

8.36±0.30

57.06

814.5

8.55±0.08

52.65

712.7

7.94±0.11

62.16

959.8

8.47±0.14

61.01

964

8.14±0.01

56.48

814.1

(2.2/1)

Homogenization- DCM/DMSO
F4
Low speed

(3.7/1)

Homogenization

DCM/DMSO

– High speed

(3.7/1)

F5

DCM – Dichloromethane; BA- Benzyl Alcohol, DMSO: Dimethyl Sulfoxide, MeOH:
Methanol
As shown in Figure 3, in terms of population distribution, the particle size of all the prepared LA
formulations and the RLD product was similar with slight differences in the size distribution. While in
terms of volume distribution, the particle size of all the prepared formulations was higher than that of
Lupron Depot®. Despite the use of the same solvent system, the prepared formulations F1 and F4 had
smaller volume mean size compared to formulations F2 and F5 due to the use of the high speed
homogenization during emulsion preparation compared to that for formulation F2 11. In contrast to this,
despite the differences in the solvent systems, formulations F1 and F2 had similar volume mean size as
that of formulations F4 and F5, respectively as a result of the use of the same homogenization speed11.
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Figure 3. Particle size and particle size distribution of Lupron Depot® and the
prepared LA microsphere formulations: A) Low burst release formulations; and B)
High burst release formulations. All values are expressed as mean±SD (n = 3
batches).
As shown in Figure 4, some irregular shapes and a highly porous polymer matrix (indicated by the red
arrow) were observed for the RLD product, Lupron Depot®. On the other hand, the prepared LA
microspheres showed a spherical shape with a smooth surface. Compared to formulations F1 and F2,
formulations F3, F4 and F5 showed a more porous structure. This may be due to the slower removal of
high boiling point BA and DMSO compared to lower boiling point MeOH11. The observed differences in
the porous structure of the prepared microsphere formulations were further confirmed and quantified by
evaluation of % porosity of the LA microsphere formulations. As shown in Table 4, differences in the %
total porosity of the formulations were observed with F3 being the most porous and F2 being the least
porous/more dense formulation.
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In addition, significant differences in the pore diameter of all the prepared formulations (Table 4)
were observed with F2 having the smallest pore diameter and F4 having the largest pore diameter. The
large pore diameter of formulation F4 is probably due to use of high boiling point DMSO as a cosolvent
compared to formulations F1 and F2, which were prepared using low boiling point MeOH as a cosolvent.
In contrast to this, despite the use of the same cosolvent, the pore diameters of F2 and F5 were smaller
than that of F1 and F4, respectively, which is probably a result of the difference in their size. The smaller
size of formulation F1 and F4 results in a shorter diffusion distance and hence, faster solvent removal and
polymer solidification leading to the formation of large pores 17. Moreover, all the prepared microspheres
had a similar polymer molecular weight of ~ 13 KDa and Tg of ~ 42°C.
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5.3.3. In vitro release testing of the risperidone microspheres:
In vitro release profiles of the RLD product (Risperdal Consta®) and the risperidone microsphere
formulations with high burst release are shown in Figure 5A. Overall, all the formulations showed similar
release duration (~36 days) but different release characteristics such as variable burst release and lag
phase. The RLD product showed the lowest burst release (~1%) followed by a lag-phase of three weeks
and then a fast release phase up to day 37. Compared to the RLD product, formulations F1 and F2 showed
a relatively high burst release (~10%) and shorter lag phase of about 17 and 20 days, respectively.
Risperidone is soluble in DCM, and hence, it may diffuse out to the surface of the microspheres during
solvent removal resulting in the relatively high burst release of formulations F1 and F2. Moreover, the
observed differences in the lag phase duration and release rate of formulations F1 and F2 may be due to
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differences in their particle size15. Compared to all other formualtions, formulation F3 had the highest
burst release followed by slow and continuous release with no lag phase. The high burst release of
formulation F3 may be due to the insolubility of risperidone in EA resulting in precipitation of
risperidone in the DCM/EA solvent system. In addition, risperidone is practically insoluble in water.
These factors together may lead to deposition of the precipitated risperidone on the microsphere surfaces.
Although the exact mechanism is unclear, similar results (high burst release) have been reported
previously for other microsphere formulations prepared using such co-precipitation method18.
The “real-time” release profiles of the risperidone microsphere formulations with low burst release
and the RLD product are shown in Figure 5B. Overall, all the prepared formulations F3 to F7 had low
burst release (~1%) similar to the RLD. However, they had a relatively shorter or no lag-phase with an
overall shorter release duration of ~ 30 days compared to ~35 days for the RLD product. The low burst
release of these formulations may be due to the use of cosolvents such as BA/MeOH leading to more
distribution of drug inside the microspheres with less accumulation on their surfaces. Shorter overall
release profiles of formulations F3 to F7 may be due to differences in drug distribution inside the
microsphere formulations resulting from dissimilarities in drug solubility in solvent systems and the
miscibility of the solvent system with water. For example, risperidone has better solubility in the
DCM/BA or DCM/MeOH compared to the EA/BA solvent system since risperidone is not soluble in EA.
Hence, risperidone will be able to diffuse along with DCM and distribute homogenously throughout the
microsphere formulations F6 and F7 during solvent removal. On the other hand, risperidone may be
entrapped in the center of microsphere formulations F4 and F5 prepared using the EA/BA solvent system
instead of achieving a more homogenous distribution. Additionally, there were differences in the particle
size and porosity of the prepared formulations, which also have the ability to alter the release
characteristics15.
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Figure 5. In vitro release profiles of the Risperdal Consta® and the prepared risperidone
microsphere formulations obtained using the USP apparatus 4 method: (A) High Burst
release formulations; and (B) Low burst release formulations.
5.3.4. In vitro release testing of the leuprolide acetate microspheres
The in vitro release profiles of the RLD product, Lupron Depot® and the prepared leuprolide acetate
microsphere formulations are shown in Figure 6. Overall, all the formulations appeared to follow
biphasic release characteristics with variable burst release followed by an apparent zero-order release due
to the slow desorption of positively charged peptide from the negatively charged acid end group of the
polymer11. Formulations F4 and F5 (30-40%) had higher burst release, similar to the RLD product
(~45%) while formulations F1, F2 and F3 had relatively low burst release phase (10-15%). The observed
differences in the burst release of the prepared formulations are due to the differences in the solvent
systems used (Table 4 ) (Figure 3)11. As discussed for risperidone microspheres, differences in the
solvent systems lead to differences in the polymer precipitation rate and drug diffusion on to the surface
of the microspheres. The rapid removal of DCM/MeOH under vacuum at room temperature, results in the
faster polymer precipitation and entrapment of the drug inside the bulk of the microspheres compared to
DCM/DMSO. Despite the similar lower burst release phase, formulation F2 had slower release compared
to formulation F1. This may be a consequence of the higher particle size, lower porosity and average pore
diameter of formulation F2 compared to formulation F1. Similarly, formulation F5 had slower release
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compared to formulation F4 due to its larger size. Compared to all other prepared LA formulations,
formulation F3 (prepared using DCM/BA) was the slowest releasing formulation with a significantly
lower release rate between days 10 and 20 despite the highest porosity and relatively larger average pore
diameter. This might be due to particle aggregation in the presence of residual organic solvent resulting
form the incomplete removal of high boiling point BA compared to cosolvents. Accordingly, the total
release duration of formulation F3 was longer (~80 % release by day 45) compared to Formulations F1
and F2 (~80 % release by day 38).
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Figure 6. In vitro release profiles of Lupron Depot® and the prepared LA microsphere
formualtions obtained using the sample and separate method: (A) Low burst release
formulations; and (B) High burst release formulations.
5.3.5. In vivo release testing of the risperidone microspheres
In vivo release profiles of the RLD product and the prepared risperidone microsphere formulations
with variable burst release are shown in Figures 7A and B. Overall, the in vivo release profiles of all
risperidone formulations have the same rank order and similar release characteristics as that of the in vitro
release profiles i.e. tri-phasic release profile with variable burst release, lag phase and fast releasing phase
(Figures 5A and B). As shown in Figure 7A, the RLD product had the lowest initial plasma
concentration with the longest lag phase of about 15 days. Formulations F1 and F2 had relatively high
burst release in vitro and accordingly, high initial plasma concentrations with a shorter lag phase of about
11 and 14 days, respectively compared to the RLD product. Whereas formulation F3 showed the highest
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initial plasma concentration followed by slow and continuous release till day 32 with no lag phase. The
observed higher initial plasma concentration of all the prepared formulations, similar to the high in vitro
burst release indicates that the absorption phase is not masking the bust release of the risperidone
microspheres. This may be because risperidone is a lipophilic drug, practically water insoluble with low
M.wt. and hence, it should have rapid absorption at the intramuscular injection site. As shown in Figure
7B, all the risperidone formulations with low in vitro burst release had low initial plasma concentrations.
Formulations F4 and F5 had a lag phase of about 5 days while Formulations F6 and F7 did not show any
lag phase, similar to their respective in vitro release profiles.
Please note that the in vivo lag phase and overall release duration of all the risperidone microsphere
formulations were shorter compared to the respective in vitro release profiles. This may be due to faster
polymer degradation as a result of the local in vivo environment such as localized pH, enzymes etc.
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Figure 7A. In vivo release of Risperdal Consta® and the prepared risperidone microspheres in a rabbit
model (i.m., n=6): (A) Formulations with high burst release; and (B) Formulations with low burst
release.
5.3.6. In vivo release testing of the leuprolide acetate microspheres
The in vivo release profiles of the RLD product, Lupron Depot® and the prepared LA microsphere
formulations are shown in Figure 8. The RLD product had high initial plasma concentration similar
to the high in vitro burst release followed by slow and continuous release over a 40-day period. All
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the prepared LA microsphere formulations showed relatively low initial plasma concentrations
followed by slow and continuous zero–order release over a 40-day period, similar to the in vitro
release characteristics (Figure 6). Moreover, the in vivo release profiles of all the LA microsphere
formulations including the RLD products were shorter with faster release rates compared to their in
vitro release profiles, as discussed above for risperidone microspheres.
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Figure 8. In vivo release profile of Lupron Depot® and the prepared leuprolide acetate
microspheres in a rabbit model (i.m., n=6) ): (A) Formulations with low burst release; and (B)
Formulations with high burst release.

5.3.7. Development of IVIVCs:
Development of IVIVCs was performed using a two-stage deconvolution approach with time
scaling/shifting factors as described in the U.S. FDA guidance1.
5.3.7.1. Deconvolution of the in vivo release profiles to the fraction absorbed
The in vivo plasma concentration vs time (PK) profiles (i.m.) of the risperidone and LA microspheres
were deconvoluted into the fraction absorbed vs time (Figue 9) using the Loo-Riegelman method

[11,15,16

.

Overall, the in vivo release profiles of all the formulations had the same rank order as their respective in
vitro release profiles: 1) risperidone microspheres with high burst release – F7>F6>F5> F4>RLD; 2)
risperidone microspheres with low burst release – F3> F2> F1> RLD; 3) LA microspheres with low burst
release - RLD>F1>F2>F3 and, 4) LA microspheres with high burst release - RLD>F4>F5. However, the
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deconvolved in vivo release from PLGA microspheres appeared to be faster compared to their in vitro
release profiles, as discussed above. Apart from this, no other significant differences in the release
characteristics, especially the burst release phase under in vitro and in vivo conditions were observed for
risperidone microspheres. Whereas, in the case of LA microspheres, the in vivo release profiles of all the
formulations including the RLD product showed significantly lower in vivo burst release (Figure 9C and
D) compared to the respective in vitro burst release profiles. This indicates that absorption of LA at the
intramuscular site is slow due to its hydrophilic nature and larger size compared to risperidone, resulting
in the masking of the in vivo burst release of the LA microspheres.
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Figure 9. Deconvolved in vivo profiles (fraction absorbed/released) of the compositionally
equivalent microspheres (deconvolved using the Loo-Riegelman method): (A) Risperidone
microspheres – High burst release formulations, (B) Risperidone microspheres – Low burst release
formulations, (C) LA microspheres with low burst release formulations and, (D) LA microspheres
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with high burst release formulations.

5.3.7.2. Establishment of IVIVC between in vitro and in vivo fraction released/absorbed
In order to develop IVIVCs, different combinations with a minimum of two or three formulations with
different release rates were used. For risperidone as well as LA microspheres, the formulations were
grouped as low and high burst release to minimize the impact of variable burst release on the
predictability of the developed IVIVCs15,19. In the case of LA microspheres, the RLD product, Lupron
Depot®, with high burst release was used as an external formulation for the IVIVC developed using the
high burst release formulations. Based on the knowledge obtained from our previous research on
microspheres15,19, formulations on the extremes of the release profile range (for example, formulations F1
and F3 for the risperidone microspheres with low burst release) were included in the combinations of
formulations used to develop correlation models.
First, the in vitro release profiles were simulated via model fitting using Origin Pro (data analysis
software) to synchronize the sampling time interval with the in vivo release profiles. Due to the
differences in the % burst release and release rate of the in vitro and deconvoluted in vivo release profiles,
time scaling and time shifting factors (determined using a Levy plot - in vivo vs in vitro time for definite
fraction released) were used to achieve a 1:1 correlation. In the case of risperidone microspheres, only one
factor i.e. a time scaling factor of 1/1.85 for high burst release formulations and a time shifting factor of 11 for low burst release formulations was used to compensate for differences in the in vitro and in vivo
release rate. For LA formulations, two factors i.e. a time-scaling factor of 1/1.65 and a time-shifting factor
of +1 were used to adjust for differences in the burst release and the release rate under in vitro and in vivo
conditions, respectively. The same time-scaling/shifting factors were applied to all formulations in each
group used for the development and validation of the IVIVCs. The fraction absorbed/released in vivo of
the selected formulations was plotted against the fraction released in vitro at the respective time point to
establish a correlation if any. A total of four different IVIVC models based on the different groups of
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risperidone and LA microsphere formulations were developed as shown in Figure 10 A, C, E and G.
Affirmative point-to-point correlation IVIVCs i.e. a Level A (as per the U.S. FDA guidance1) between the
fractions released in vitro and the fractions released/absorbed in vivo were obtained for all the groups
using a simple linear regression model (correlation coefficients greater than 0.95). Please note that all the
developed IVIVCs were different as manifested by different slopes and intercepts due to the difference in
the drug release characteristics of each group.
These developed IVIVCs were then validated for their ability to predict in vivo profiles of the external
formulation (one that was not used to develop the IVIVC model) using the respective in vitro release
profile of the external formulation. As shown in Figure 10 B, D, F and H, the predicted in vivo profiles
including burst release phase of each external formulation almost overlapped with the observed
deconvoluted in vivo release profiles.
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Figure 10. Level A IVIVCs developed using the Loo-Reigelman method
for microsphere formulations with variable burst release: (A) IVIVC 1
developed using risperidone micropshere formulations with high burst
release, F2 and F3; (B) IVIVC 1 -

experimental and predicted in

vivo release profiles of risperidone microsphere formulation F1; (C)
IVIVC 2 developed using risperidone microsphere formulations with low
burst reelase F5, F6 and F7; (D) IVIVC 2 - experimental and predicted in
vivo release profiles of risperidone microsphere formulation F4; (E)
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F3; (F) IVIVC 3 - experimental and predicted in vivo release profiles of
LA microsphere formulation F2; (G) IVIVC 4 for LA microsphere
formulations with high burst release F4 and F5; and (H) IVIVC 4 experimental and predicted in vivo release profiles of Lupron Depot®.
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The predictability of the IVIVCs were further confirmed by determination of the % prediction errors (PE)
of the developed IVIVCs for Cmax and AUC0-last using WinNonlin®. As shown in Table 3, the average
internal and external %PE for the AUC0-last and Cmax were within the recommended range of 10% or less
for IVIVC 1 developed for risperidone microspheres with high burst release phase. In case of IVIVC 2,
developed for the risperidone microspheres with low burst release phase, the average internal %PE was
not within the acceptance criteria for Cmax. However, the external % PE was within the acceptance
criteria for both Cmax and AUC0-last (Table 3). Similarly, in the case of IVIVC 3 for LA microspheres, the
average internal %PE was not within the acceptance criteria for Cmax. However, the external % PE was
within the acceptance criteria for both Cmax and AUC0-last (Table 3). Also, the average internal and
external %PE for the AUC0-last and Cmax were within the recommended range of 10% or less (Table 3) for
the IVIVC 4 developed for LA microspheres with high burst release phase. Thus, all four developed
IVIVCs are acceptable in terms of their ability to predict the in vivo performance of the microspheres.
Table 3. Validation of the developed IVIVCs for risperidone and LA microspheres

Cmax (μg/l)
Validation

Obs.

AUC0-last (μg/l * day)
Pred.

%PE

Obs.

Pred.

%PE

IVIVC 1 – Risperidone microspheres with high burst release
Average

29.46

30.22

3.10

230.62

215.25

6.23

19.99

20.56

2.87

202.92

184.55

-9.05

Internal (F2,
F3)
External (F1)

IVIVC 2 - Risperidone microspheres with low burst release
Average

30.31

39.45

29.77
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299.88

283.78

5.84

Internal
(F5,F6,F7)
External F4

39.98

41.27

3.24

237.09

228.05

-3.81

IVIVC 3 – LA microspheres with Low burst release phase
Average

3.20

3.82

31.49

65.15

63.05

14.89

4.22

4.03

-4.40

66.97

60.95

-8.98

Internal
(F2,F3)
External (F1)

IVIVC 4 – LA microspheres with Low burst release phase
Average

6.61

6.42

2.64

75.50

71.20

4.60

0.49

10.35

9.07

69.03

62.48

-9.48

Internal
(F4,F5)
External
(Lupron

Depot®)

Following this, in order to demonstrate the impact of significantly variable burst release on the
predictability of the IVIVCs, the in vivo release profile of the RLD product, Risperdal Consta® (with very
low burst release) was predicted from its in vitro release profile using the IVIVC 1 and 2 models
developed for the prepared risperidone microsphere formulations. As shown in Figure 11, the in vivo
release profile of the RLD product was not predicted using the IVIVC 1 model but was predicted using
the IVIVC 2 model. The differences in the predictability were further confirmed by the determination of
%PE. As shown in Table 4, in case of IVIVC 1, %PE for Cmax (-0.1%) was within the acceptance criteria
of 10% but that of the AUC0-last (-28.81%) was higher than 10%. While in the case of IVIVC 2, both
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%PEs for Cmax (10.30%) and AUC0-last (-0.70%) were within the acceptance criteria of 10%. This is
because IVIVC 2 was developed using the formulations with low burst release similar to the RLD
product, unlike IVIVC 1, which was developed using formulations with relatively high burst release.
Accordingly, IVIVC 1 was not able to predict the in vivo profiles of the prepared risperidone formulation
F4 with low burst release (Figure 11), with %PE for Cmax and AUC0-last higher than 10% (Table 4).
Similarly, IVIVC 2 developed using the risperidone formulations with low burst release phase was not
able to predict the in vivo profiles of the prepared risperidone formulation F3 with high burst release
(Figure 11), with %PE for Cmax higher than 10% (Table 4).
The impact of variable burst release phase on the predictability of the IVIVCs developed for LA
microspheres

was

investigated

to

determine

the

influence

of

molecular

properties

(hydrophobicity/hydrophilicity and molecular weight) on the predictability of IVIVCs of such complex
drug products. As shown in Figure 11, the in vivo release profile of the RLD product, Lupron Depot®
(with very high burst release) was not predicted using IVIVC 3 developed using formulations with low
burst release phase. The differences in the predictability were further confirmed by determination of the
%PE. As shown in Table 4, in case of IVIVC 3, %PE for a AUC0-last (4.21%) was within the acceptance
criteria of 10% but that of the Cmax (40.06%) was higher than 10%. Similarly, IVIVC 4, developed using
the LA formulations with high burst release phase, was not able to predict the in vivo profiles of LA
formulation F3 with low burst release (Figure 11) as confirmed by the %PE for Cmax and AUC0-last being
higher than 10% (Table 4).
These results suggest that significant variation in the burst release phase compromises the ability of the
IVIVCs to predict the in vivo performance of microspheres and accordingly, IVIVCs for microspheres
should be developed using formulations with less variation in the burst release phase.
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Figure 11. Experimental vs predicted in vivo release profiles obtained
using the respective developed IVIVCs. - Risperdal Consta®, prepared
risperidone micropsheres and Lupron Depot® and prepared LA
micropsheres.

Table 4. Predictability of the developed IVIVCs for the Risperdal Consta®

Cmax (μg/l)
Validation

Obs.

Pred.

AUC0-last (μg/l * day)
%PE
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Obs.

Pred.

%PE

IVIVC 1 – Risperidone microspheres with high burst release
Risperdal
Consta®

38.29

37.32

-0.10

247.14

175.93

-28.81

39.98

31.42

-21.39

237.09

162.72

-31.37

F4_Low
burst
IVIVC 2 - Risperidone microspheres with low burst release
Risperdal
®

38.29

39.51

10.30

247.14

245.42

-0.70

43.94

61.54

40.06

288.33

300.46

4.21

Consta

F3_High
burst
IVIVC 3 – LA microspheres with Low burst release phase
Lupron
Depot®

9.49

10.58

11.48

69.03

62.36

-11.11

IVIVC 4 – LA microspheres with High burst release phase
F3_Low
3.53

5.36

51.50

75.42

65.68

12.91

burst

5.4. Conclusions:
Affirmative level A IVIVCs were developed for the first time with the ability to predict in vivo release
characteristics including high as well low burst release phase for parenteral microspheres containing two
different therapeutic molecules. It was shown that developing IVIVCs using formulations with less
variation in the burst release phase significantly improved their ability to accurately predict the drug
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release characteristics, specifically the burst release phase of microspheres. However, it was also shown
that the complexity and predictability of IVIVCs is sensitive to the type of burst release phase and hence,
IVIVCs developed using a low burst release phase can not be used to predict formulations with high burst
release and vice versa. This may limit the application of the IVIVCs to serve as a surrogate only for
complex drug products with similar burst release phases. This work has provided a comprehensive
understanding on the significance of variable burst release on the development and predictability of
IVIVCs for microsphere drug products. This moves the field a step closer towards the development of
IVIVCs in human for such complex parenteral drug products.
Together with our previous research on developing a Level A IVIVCs for polymeric microspheres
containing small molecules and peptides, it can be concluded that Level A IVIVCs can be developed for
complex parenteral microsphere drug products using in vitro release testing methods and a rabbit model.
This highlights the potential of developing IVIVCs using clinical data for such complex parenteral drug
products, which can serve as a surrogate for bioequivalence studies.
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Chapter 6

Conclusions and Future Studies

138

6.1. Conclusions
The present work describes for the first time that Level A IVIVCs can be developed for
variety of compositionally equivalent parenteral PLGA microsphere products (containing small
molecule as well as large molecular weight and complex molecules such as peptides) with
different physicochemical properties and drug release characteristics. It was observed that a
combination of formulations with significant variation in the release rate as well as burst release,
have the potential to alter the complexity and predictability of the IVIVC models. Hence,
IVIVCs of parenteral PLGA microspheres should be developed using formulations that cover a
wide range of release rates but with less variation in their burst release phase. Also, the slow
absorption of peptide at the intramuscular site showed the potential to mask the high burst
release that is observed under in vitro release testing conditions, which in turn complicates the
development of IVIVCs for such products. Thus, fundamental and comprehensive understanding
on the development, complexity and predictability of IVIVCs for parenteral polymeric
microspheres was achieved by investigating three different types of microsphere products. The
development of Level A IVIVCs for complex parenteral microsphere drug products using a
rabbit model highlights the feasibility of developing IVIVCs using clinical data to serve as a
surrogate for bioequivalence studies.
The present work also describes that the minor manufacturing changes (solvent systems,
mixing methods/speed/time, solvent removal process) have the potential to alter the
physicochemical properties (particle size, porosity, drug distribution), as well as drug release
characteristics (release rate, duration) and hence, in vivo performance of a variety of
compositionally equivalent parenteral PLGA microsphere drug products. This is significant for
high-risk products such as microspheres containing a substantial amount of potent drugs. The
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comprehensive evaluation of two different types of products has helped to identify critical
quality attributes that have the potential to alter the drug release characteristics of Q1/Q2
equivalent microspheres. It was also determined that additional CQAs may need to be
investigated for peptide microspheres such as pore diameter/pore structure, emphasizing the need
to establish product specific CQAs. The identified CQAs can be used as in vitro characterization
tools to describe Q3 (microstructure) sameness of the Q1/Q2 equivalent PLGA microspheres.
This knowledge will be helpful to regulatory authorities as well as the pharmaceutical industry
during scale up, post approval manufacturing changes and for generic drug product development.
Moreover, the developed USP apparatus 4 (naltrexone) as well as sample and separate
(LA) based in vitro release testing methods have the potential to be used as a quality control
tools to discriminate Q1/Q2 equivalent microspheres prepared with manufacturing differences
and most importantly, as a bio-relevant method to predict the in vivo performance of these
microspheres. The significant reduction in testing duration as well as discriminatory ability of the
developed accelerated USP apparatus 4 release testing method shows its potential to be used as a
quality control tool to assure product performance as well as assist in product development for
naltrexone microspheres.
Lastly, it was determined that the hydrolytic degradation kinetics of low molecular
weight PLGA microspheres is not sensitive to differences in their particle size and porosity.
However, the drug release characteristics of such microspheres containing relatively large
hydrophilic molecules (peptides) were sensitive to changes in their pore structure/network.
6.2. Future studies
The Level A IVIVCs in the present work have been developed using an animal model
(Rabbit). However, considering the interspecies differences between animals and humans,
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further investigation is necessary to determine whether an IVIVC can be developed using clinical
data. Moreover, it will be helpful to explore the application of the developed IVIVCs for the
prediction of in vivo performance of compositionally equivalent microspheres prepared with
changes in formulation parameters, polymer source variations etc.
Our research on PLGA based in-situ forming implants has shown that polymer source
variation can lead to significant changes in drug release characteristics. Based on these findings
as well as the knowledge gained from the present work on the sensitivity of PLGA microspheres
to minor changes in manufacturing processes, it is critical to investigate that impact of polymer
source variations (minor changes in polymer characteristics such as lactic to glycolic acid ratio,
random monomer sequences as well as microstructure) on any alterations of drug release
characteristics of Q1/Q2 equivalent parenteral PLGA microspheres in order to ensure their
consistent performance and safety.
The present work also suggested that differences in drug distribution in the PLGA
microspheres has the potential to alter drug release characteristics. Accordingly, it will be
essential to investigate the drug distribution for such complex drug products using advanced
characterization techniques with an ability to determine elemental distribution.
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